Are you the publisher? Claim or contact us about this channel


Embed this content in your HTML

Search

Report adult content:

click to rate:

Account: (login)

More Channels


Channel Catalog


Channel Description:

ACN Newswire press release news - Recent Press Releases

older | 1 | .... | 303 | 304 | (Page 305) | 306 | 307 | .... | 320 | newer

    0 0

    BOSTON, Oct 22, 2018 - (ACN Newswire) - Catastrophe risk modeling firm AIR Worldwide today announced it has developed a probabilistic model for cyber risk capable of accounting for security breach and cloud service provider downtime incidents for insurance portfolios worldwide. The new model will be included in the latest release of ARC (Analytics of Risk from Cyber), AIR's cyber risk modeling and analytics platform, due for general release on October 31, 2018. AIR Worldwide is a Verisk (Nasdaq:VRSK) business.

    "Many insurers are challenged to understand how often various types of cyber incidents can occur and how they can affect the performance of their book," said Prashant Pai, vice president of cyber offerings at Verisk. "As a result, decisions on product development, underwriting, portfolio optimization, and capital allocation tend to be made with limited data; and too much weight is often put on intuition or broad assumptions. This is where probabilistic modeling can help the industry better manage cyber risk globally."

    AIR's probabilistic cyber model estimates the likelihood, severity, and economic and insurance impact of security breach and cloud service provider downtime incidents; cloud service provider downtime incidents are one of the most likely forms of aggregation risk for cyber. The new AIR cyber model has been calibrated with public, commercial, and insurance claims data that includes information on more than 60,000 worldwide incidents and the cybersecurity profile of over 100,000 organizations globally.

    "The detail and quality of the data we have has allowed us to apply innovative stochastic and machine learning techniques to create a model that provides granular output," said Scott Stransky, assistant vice president and director of emerging risk modeling at AIR. "By training our machine learning model on real claims data, the model can differentiate the risk by technographic parameters such as cybersecurity practices, cloud service provider, and the cause of cloud downtime incidents, in addition to firmographic characteristics such as company size and sector. AIR's philosophy is to be transparent and flexible about the various modeling assumptions we've made, and model users can dig into them and truly own the risk. Additionally, we've collaborated with development partners to allow outputs to be displayed to our users at the organization level."

    Ian Newman, partner and global head of cyber at Capsicum Re, said, "We're excited to be both one of the first users of AIR's new probabilistic cyber model and a part of the model's development. Making use of AIR's cutting-edge model will help our current and prospective clients better understand their cyber exposures. It will reinforce our ability to develop and deliver innovative cyber insurance solutions, such as cyber industry loss warranties (ILWs), and work with insurance-linked securities (ILS). We also believe analytics are key to the market of the future, which will consist of three core classes: property, casualty, and cyber (PC&C)."

    Pai concluded, "The AIR cyber model is the output of several years of work by experts across all of Verisk in the fields of cybersecurity, data science, underwriting, and catastrophe modeling. Our mission is to help the cyber insurance industry grow profitably, and this model will help us take a big leap forward."

    In addition to the probabilistic model, the latest version of ARC features functionality to help insurers understand their additional risk due to GDPR, the expansion of AIR's cyber industry exposure database to regions globally, and many other enhancements.

    About AIR Worldwide

    AIR Worldwide (AIR) provides risk modeling solutions that make individuals, businesses, and society more resilient to extreme events. In 1987, AIR Worldwide founded the catastrophe modeling industry and today models the risk from natural catastrophes, terrorism, pandemics, casualty catastrophes, and cyber incidents. Insurance, reinsurance, financial, corporate, and government clients rely on AIR's advanced science, software, and consulting services for catastrophe risk management, insurance-linked securities, longevity modeling, site-specific engineering analyses, and agricultural risk management. AIR Worldwide, a Verisk (Nasdaq:VRSK) business, is headquartered in Boston, with additional offices in North America, Europe, and Asia. For more information, please visit www.air-worldwide.com.

    ###

    This announcement is distributed by West Corporation on behalf of West Corporation clients.
    The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
    Source: AIR Worldwide via Globenewswire

     
    Copyright 2018 ACN Newswire. All rights reserved. www.acnnewswire.com

    0 0

    Will reduce food wastage and inefficiencies by visualizing refrigerator temperatures

    TOKYO, Oct 23, 2018 - (JCN Newswire) - NTT DOCOMO, INC. and NTT DOCOMO USA, Inc. announced today the immediate launch of an IoT-driven temperature- and humidity-monitoring service for industrial refrigerators and freezers in the United States. Customers can use smartphones or PCs to monitor the temperature and humidity of their equipment, get alerts in the event of any abnormality, receive monthly reports on temperature and humidity trends, and change settings based on such reports. The subscription service is available from $99 per month in the United States.

    DOCOMO developed the service in collaboration with myDevices, an IoT solutions company based in Los Angeles, California that provides IoT technology based on LoRa, a wireless data communication technology for low-power, extra-long-range transmissions. Temperature and humidity data collected at grocery stores and restaurants are available in the cloud in real time for reliable temperature management, including efficient automation of processes such as visual confirmations by employees, and reduced food wastage.

    The system uses the LoRaWAN specification, a low-power, wide area networking protocol introduced by the LoRa Alliance, which enables sensors to run for more than five years without replacement.

    Refrigeration temperature management is an important issue for grocery stores and restaurants, because equipment breakdowns can lead directly to food spoilage. Despite the high demand for industrial refrigerators with remote monitoring functionality, such equipment is expensive and replacement cycles can be long, so many refrigerators without such functionality are operating in the U.S. market.

    The new service has been launched under DOCOMO's "Globiot" global IoT initiative, which was introduced on July 2 to provide global connectivity and operational support and consulting to Japanese enterprises that have global IoT operations. Going forward, DOCOMO and DOCOMO USA expect to continue collaborating with cutting-edge U.S. companies to introduce additional IoT solutions that help customers raise their productivity and create new value.

    About NTT DOCOMO

    NTT DOCOMO, Japan's leading mobile operator with over 76 million subscriptions, is one of the world's foremost contributors to 3G, 4G and 5G mobile network technologies. Beyond core communications services, DOCOMO is challenging new frontiers in collaboration with a growing number of entities ("+d" partners), creating exciting and convenient value-added services that change the way people live and work. Under a medium-term plan toward 2020 and beyond, DOCOMO is pioneering a leading-edge 5G network to facilitate innovative services that will amaze and inspire customers beyond their expectations. DOCOMO is listed on the Tokyo Stock Exchange (9437). https://www.nttdocomo.co.jp/english/.

    Contact:
    NTT DOCOMO International PR Public Relations Department Tel: +81-3-5156-1366 Fax: +81-3-5501-3408 URL: www.nttdocomo.com Contact: https://nes.nttdocomo.co.jp/PINQ01/showinquiry.do

    Copyright 2018 JCN Newswire. All rights reserved. www.jcnnewswire.com

    0 0

    TOKYO, Oct 23, 2018 - (JCN Newswire) - Hitachi Nuclear Energy Europe, Ltd., a wholly-owned subsidiary of Hitachi, Ltd. (TSE: 6501), today announced the appointment of three additional partners to support delivery of Wylfa Newydd - each one a significant UK employer.

    Assuming a successful project outcome, Hitachi will deliver the Nuclear Island and Architect Engineering for the proposed Wylfa Newydd development on the Isle of Anglesey, under contract to Horizon Nuclear Power (also a Hitachi, Ltd. Subsidiary).

    Atkins, a member of the SNC-Lavalin Group, will support on Civil Engineering design for the Nuclear Island; KBR will work on Project Controls; and Wood, a UK headquartered global engineering firm, will support Architect Engineering.

    Hitachi Nuclear Energy Europe Project Director Eric Chassard said:

    "Wood, has been involved in every nuclear new build in UK history. KBR and Atkins are also world leaders in their fields - with clear and proven experience on projects of this scale and complexity. The pedigree, expertise and detailed knowledge of all three partners are second to none.

    "We are rapidly developing a team of the world's most capable companies as we prepare to deliver the Nuclear Island and Architect Engineering for Wylfa Newydd, and couldn't have found stronger partners to support us.

    "This is one more step in the UK's growing domestic expertise around UK ABWR technology. A chance for UK workforces to play a role at the heart of technical delivery for the Wylfa Newydd project, and to further spread the economic benefit through the UK supply chain.

    "Once operational, Horizon's plant at Wylfa Newydd will produce some 2.9GW of clean, secure and affordable electricity - and its development will provide once-in-a-generation economic opportunities for the UK nuclear industry, and the region of North West Wales."

    Horizon Nuclear Power is developing plans to build at least 5.8GW of new nuclear power generation plant at Wylfa on the Isle of Anglesey and Oldbury-on-Severn in South Gloucestershire. Its power station sites will employ up to 850 people each once operational with a construction workforce expected to peak at 9,000.

    Hitachi Nuclear Energy Europe, Ltd. - in collaboration with Hitachi-GE Nuclear Energy, Ltd. - will work under contract to Horizon as Architect Engineer for the project, and as provider of Engineering and Procurement for the Nuclear Island. The Architect Engineer is responsible for design integration and technical consistency across all aspects of the plant.

    Each partner will operate directly under contract to Hitachi Nuclear Energy Europe, Ltd. and these contracts reflect the significant work underway to support preparation for construction of the plant.

    About Hitachi Nuclear Energy Europe, Ltd.

    Hitachi Nuclear Energy Europe, Ltd. provides local management and delivery of Hitachi's nuclear business in the UK and Europe, drawing on expertise and products which have been developed through our extensive experience in the civil nuclear sector. Hitachi Nuclear Energy Europe, Ltd. is a UK-registered 100% subsidiary of Hitachi, Ltd. The company was formed in 2015 and began operations on 1st April 2016.

    Hitachi is a leading provider of nuclear goods and service worldwide, largely working through our joint venture with General Electric - Hitachi-GE Nuclear Energy, Ltd. Hitachi's nuclear expertise spans design, manufacture, inspection, installation, pre-operation, and maintenance of nuclear equipment. The company also delivers integrated project management, and has been involved with the successful delivery of 23 reactors to date.

    About Our Partners

    SNC-Lavalin acquired WS Atkins plc on July 3, 2017. Atkins (www.atkinsglobal.com) is one of the world's most respected design, engineering and project management consultancies, employing some 18,300 people across the UK, North America, Middle East, Asia Pacific and Europe. Atkins builds long term trusted partnerships to create a world where lives are enriched through the implementation of our ideas. Founded in 1911, SNC-Lavalin is a global fully integrated professional services and project management company and a major player in the ownership of infrastructure. From offices around the world, SNC-Lavalin's employees are proud to build what matters. Teams provide comprehensive end-to-end project solutions - including capital investment, consulting, design, engineering, construction, sustaining capital and operations and maintenance - to clients in oil and gas, mining and metallurgy, infrastructure and power.

    KBR (Kellogg, Brown and Root (KBR) Limited, United Kingdom) is a leading global provider of full life-cycle professional services, project delivery and technologies supporting the Government Services and Hydrocarbons markets, creating exceptional value for customers, employees and shareholders. KBR has a rich history acting as a programme management contractor on many of the world's largest and most complex programmes and with an excess of 30,000 employees operating in over 40 countries, KBR is one of the world's premiere engineering, procurement, construction and programme management companies.

    Wood is a global leader in the delivery of project, engineering and technical services to energy and industrial markets. Wood operates in more than 60 countries, employing around 60,000 people, with revenues of over $10 billion. Wood provides performance-driven solutions throughout the asset life cycle, from concept to decommissioning across a broad range of industrial markets, including the upstream, midstream and downstream oil & gas, power & process, environment and infrastructure, clean energy, mining, nuclear, and general industrial sector.

    About Hitachi, Ltd.

    Hitachi, Ltd. (TSE: 6501), headquartered in Tokyo, Japan, delivers innovations that answer society's challenges, combining its operational technology, information technology, and products/systems. The company's consolidated revenues for fiscal 2017 (ended March 31, 2018) totaled 9,368.6 billion yen ($88.4 billion). The Hitachi Group is an innovation partner for the IoT era, and it has approximately 307,000 employees worldwide. Through collaborative creation with customers, Hitachi is deploying Social Innovation Business using digital technologies in a broad range of sectors, including Power/Energy, Industry/Distribution/Water, Urban Development, and Finance/Social Infrastructure/Healthcare. For more information on Hitachi, please visit the company's website at http://www.hitachi.com.

    Contact:
    Hitachi Ltd Corporate Communications Tel: +81-3-3258-1111

    Copyright 2018 JCN Newswire. All rights reserved. www.jcnnewswire.com

    0 0

    TOKYO, Oct 23, 2018 - (JCN Newswire) - Eisai Co., Ltd. and Meiji Seika Pharma Co., Ltd. announced that an application seeking manufacturing and marketing approval in Japan was submitted as of today by Meiji for the Parkinson's disease treatment ME2125 (safinamide mesylate, "safinamide").

    This application is primarily based on a double-blind, placebo-controlled Phase II/III study to evaluate the efficacy and safety of safinamide as add-on therapy, as well as an open label Phase III study to evaluate the safety and efficacy of long-term administration of safinamide in Japanese patients with Parkinson's disease with wearing-off phenomenon(*) who are currently receiving levodopa.

    Under the license agreement signed between Eisai and Meiji in March 2017, Eisai has the exclusive rights to market safinamide in Japan, as well as to develop and market safinamide in Asia(**). Meiji conducted clinical trials, and then submitted a manufacturing and marketing authorization application for the drug in Japan. Eisai will submit applications for manufacturing and marketing approval for the drug in Asia.

    Through the development of safinamide, Eisai and Meiji will make further contributions to address the diversified needs of, and increase the benefits provided to, Parkinson's disease patients and their families.

    (*) Wearing off phenomenon: As the disease progresses, levodopa's duration of effect ("on" time) decreases, and Parkinson's disease symptoms return before the next dose
    (**) South Korea, Taiwan, Brunei, Cambodia, Laos, Malaysia, the Philippines, Indonesia, Thailand, Vietnam, Myanmar, Singapore, Hong Kong, Macao

    About safinamide mesylate (generic name, development code: ME2125)

    Safinamide is a selective monoamine oxidase B (MAO-B) inhibitor, which reduces the degradation of excreted dopamine, helping to maintain the density of dopamine in the brain. Additionally, safinamide blocks sodium ion channels and inhibits glutamate release, and as such, has potential as a new Parkinson's disease treatment which possesses both dopaminergic and non-dopaminergic mechanisms. Global clinical trials of safinamide in combination with levodopa for the treatment of mid- to late-stage Parkinson's disease showed extended "on" time and an improvement in motor function.(1),(2)

    Safinamide was discovered and developed by Newron Pharmaceuticals S.p.A. In 2011, Newron entered into a licensing agreement with Meiji, granting Meiji exclusive rights to develop, manufacture and commercialize the drug in Japan and Asia. Safinamide is marketed under the name "Xadago" in 15 countries in Europe and the United States.

    About the Phase II/III Clinical Study (ME2125-3)

    Study ME2125-3 was a multicenter, double-blind, placebo-controlled, randomized, parallel group study to evaluate the efficacy and safety of two doses of safinamide (50 and 100 mg, once a day for 24 weeks) administered orally as add-on therapy in Japanese patients with Parkinson's disease with wearing-off phenomenon who are currently receiving levodopa. In this study, the primary endpoint was the change in mean daily "on" time from baseline to 24 weeks of the treatment phase, and verified the superiority of each dose of safinamide over placebo.

    About the Phase III Clinical Study (ME2125-4)

    Study ME2125-4 was an open-label, multicenter study to evaluate the long-term efficacy and safety of two doses of safinamide (50 and 100 mg, once a day for 52 weeks) administered orally as add-on therapy in Japanese patients with Parkinson's disease with wearing-off phenomenon who are currently receiving levodopa. In this study, in addition to evaluating the safety of long-term administration of safinamide, the study evaluated the change in mean daily "on" time from baseline to 52 weeks of the treatment phase as the primary efficacy endpoint.

    About Parkinson's Disease

    Parkinson's disease is a neurodegenerative disease which causes motor impairment, including shaking in the limbs, muscular rigidity and shuffling gait. It is caused by degeneration of the dopamine nervous system, which leads to a shortage of dopamine, a neurotransmitter in the brain.

    According to Eisai's internal estimates, there are approximately 300,000 patients suffering from Parkinson's disease in Asia (excluding China and India). According to a survey by the Ministry of Health, Labour and Welfare, the number of patients suffering from Parkinson's disease in Japan numbered 163,000 in 2014.(3) The number of patients increasing due to the aging of the population.(4)

    Levodopa is widely used to treat Parkinson's disease by replenishing the brain's supply of dopamine. However, as the disease progresses, levodopa's duration of effect ("on" time) decreases, and there are cases of Parkinson's disease symptoms returning before the next dose ("wearing-off" phenomenon). To prevent the "wearing-off" phenomenon, combination therapy with a drug that has a different mechanism of action to levodopa is administered.

    About Meiji Seika Pharma Co., Ltd.

    In order to protect and improve people's health and lives, Meiji Seika Pharma, as a "Speciality and Generic Pharmaceuticals Company," runs its pharmaceutical business in the two main fields, infectious disease and central nervous system disorders, as well as generic drugs. Meiji Seika Pharma strives to respond to diversified medical needs and contributes to the well-being of people worldwide.

    (1) Borgohain R et al. Randomized Trial of Safinamide Add-On to Levodopa in Parkinson's Disease With Motor Fluctuations. Mov Disord. 2014 Feb;29(2):229-37
    (2) Schapira AH et al. Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial. JAMA Neurol. 2017 Feb 1;74(2):216-224
    (3) Patient Survey 2014 (Disease and Injury) by Statistics and Information Department, Minister's Secretariat, Ministry of Health, Labour and Welfare
    (4) Japan Intractable Diseases Information Center: http://www.nanbyou.or.jp/

    About Eisai

    Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our human health care philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Oncology and Neurology.

    As a global pharmaceutical company, our mission extends to patients around the world through our investment and participation in partnership-based initiatives to improve access to medicines in developing and emerging countries.

    For more information about Eisai Co., Ltd., please visit www.eisai.com.

    Contact:
    Meiji Seika Pharma Co., Ltd. Public Relations Tel: +81-(0)3-3273-5614 Eisai Co., Ltd. Public Relations Department TEL: +81-(0)3-3817-5120

    Copyright 2018 JCN Newswire. All rights reserved. www.jcnnewswire.com

    0 0

    HONG KONG, Oct 23, 2018 - (ACN Newswire) - The well-known cryptocurrency exchange HitBTC announced today that Blockpass' PASS token has successfully been listed on the platform. The PASS Token is an ERC20 KYC standard utility token that serves as a discount token on the Blockpass platform.

    For both the exchange and Blockpass, this token listing is an exciting achievement. PASS tokens are of the first-of-its-kind KYC token standard. This means that in order to exchange the token, the token holder is required to possess a certified KYC-compliant identity. The KYC token standard is an important innovation as the digital economy becomes more and more regulated, worldwide.

    "We're really pleased to announce that PASS is now trading on HitBTC! We have been working hard to ensure that are building a strong and cohesive ecosystem of partners," said Adam Vaziri, CEO of Blockpass. "We are expanding the offering of PASS, our pioneering KYC-forward token, on multiple exchanges. PASS is not just a discount voucher for Blockpass KYC offerings and a reward for identity verification, it is a testament to Blockpass' positioning as the leading compliance tool for security token offerings."

    Blockpass has announced a number of key partnerships in recent months, most notably the establishment of a world-first advanced blockchain identity research laboratory, the Blockpass Identity Lab, in collaboration with Edinburgh Napier University. In addition, Blockpass announced its partnership and commitment to collaboration with token trading platform Ethfinex last week. Through this partnership, traders using the Ethfinex platform will be able to create a user-centric verified identity profile that can be used to allow instantaneous access to participation in ICOs on Ethfinex.

    About Blockpass IDN
    The goal of Blockpass IDN (http://www.blockpass.org/) is global realization of identity for the Internet of Everything. Through the use of blockchain technology and smart contracts, Blockpass is a production ready Regtech platform offering shared regulatory and compliance services for humans, businesses, objects and devices. As this identity system supports verification of humans (KYC), objects (KYO) and connected devices (KYD), it will enable the development of new applications that rely on a trusted connection between human, corporate, and device identities. Registered in Hong Kong, Blockpass IDN is a joint venture of Infinity Blockchain Labs and Chain of Things. Blockpass IDN licenses its technology from the non-profit Blockpass Foundation, registered in the Isle of Man.

    For more information and updates, please visit and sign up to the following:
    Promotional video: https://youtu.be/SvO2cw3e-SI
    Website: http://www.blockpass.org
    Medium: https://medium.com/@blockpass
    Twitter: https://twitter.com/BlockpassOrg
    Facebook: https://www.facebook.com/blockpassorg/
    Telegram: https://t.me/blockpass

    Contact: Caitlin Betts, +852 9733 4935, press@blockpass.org


     
    Copyright 2018 ACN Newswire. All rights reserved. www.acnnewswire.com

    0 0

    The investment will bring rapid expansion in the deployment of Eyesight's Automotive Edge Computer Vision AI solutions globally

    HONG KONG, Oct 24, 2018 - (ACN Newswire) - Eyesight, the leading computer vision company which brings Edge-based Computer Vision and AI solutions to the automotive and IoT markets, announced today a $15m growth investment round, led by Jebsen Capital, Arie Capital, Mizrahi Tefahot, among other investors.

    Investment to Drive Future Growth
    Already working with some of the world's leading companies, Eyesight will be leveraging the investment to further expand the company's fast-growing Edge Computer Vision and AI footprints.

    These technologies are key in shaping user interactions in automotive and smart home environments and are critical to human safety in vehicles. The company's Driver Monitoring and Occupancy Monitoring System tracks the drivers' attention on the road and behaviour in the cabin to dramatically reduce the millions of car accidents that occur annually.

    Eyesight's in-cabin sensing capabilities are set to be increasingly integrated into new vehicles, aligning with the recruitments for such systems in Autonomous vehicles and Euro NCAP's safety recommendations that is calling automakers to include driver monitoring systems in vehicles launched by 2020. The latest growth round will fuel Eyesight's expansion globally, putting its cabin sensing technologies in additional car models on the road, as one of the market's key technology providers.

    Eyesight's solution monitors the driver's gaze direction, pupil dilation, eye openness, head position, among other visual attributes to enable alerts when signs of drowsiness or distraction are detected. Eyesight's technology further detects cabin occupancy to enable real-time optimization of safety systems according to passengers present, helping reduce possible injuries and keep passengers safe.

    The company's proprietary technology is backed by over 22 granted patents, utilizing advanced computer vision and artificial intelligence algorithms to deliver market-leading performance. Eyesight's technology is optimized for edge processing on the device in real-time, offering high accuracy with lean requirements, while ensuring full privacy to the end user.

    Rebranding Reflects Leadership Position in Edge Computer Vision and AI
    When announcing the funding round, the company also showed off the fruits of its rebranding campaign, including its all-new logo. The new look reflects the company's focus on Edge Computer Vision AI and depicts its sensing capabilities. The logo evokes the nature of the company's inteligent technology inspired by the human eye, scanning and motion used to understand users, their actions, and predict their needs, to deliver enhanced user experiences.

    About Eyesight

    Eyesight offers the most advanced edge-based Computer Vision and AI solutions. The company's technology improves daily life experiences in the car, home, and with other consumer electronics, using intelligent interactions that are responsive to users and their actions. The company's technology utilizes proprietary algorithms to deliver a range of applications: from passive sensing with the detection user presence, to active interactions using touch-free gesture control. With Eyesight's technology devices now "see" and "understand" their users, unlocking a world of enhanced user experiences.

    For more information visit www.eyesight-tech.com

    Please email inquiries to info@eyesight-tech.com


     
    Copyright 2018 ACN Newswire. All rights reserved. www.acnnewswire.com

    0 0

    - Anticipates Third Quarter Earnings per Share ("EPS") and Adjusted EPS* of $1.32 and $1.70, respectively
    - Updates 2018 Adjusted EPS Guidance to $6.80 to $7.05
    - Board Authorizes Repurchase of up to an Additional 8 Million Shares of Company's Outstanding Common Stock

    WESTCHESTER, Ill., Oct 24, 2018 - (ACN Newswire) - Ingredion Incorporated (NYSE: INGR), a leading global provider of ingredient solutions to diversified industries, today said that based on preliminary financial information, it anticipates EPS of $1.32 and adjusted EPS of $1.70, for the third quarter of 2018. For the full year, the Company anticipates adjusted EPS of $6.80 to $7.05, compared with the previously anticipated $7.50 to $7.80. During the third quarter, the Company experienced significant FX headwinds caused by weakening foreign currencies primarily in Argentina, Brazil and Pakistan, as well as the impact of Argentine peso devaluation with the adoption of hyperinflation accounting. In North America, the Company experienced several unplanned power outages at Argo, its largest sweetener plant, and these operating events resulted in unforeseen higher manufacturing and supply chain costs.

    "Our performance this quarter was impacted in part by the rapid pace and magnitude of FX currency devaluations in Argentina and Pakistan. As a result we expect our business model will require more than a quarter to recover," said Jim Gray, executive vice president and chief financial officer.

    Jim Zallie, president and chief executive officer, said, "We are disappointed with the impact these unexpected circumstances had on our results during the latter half of the quarter, and remain focused on aggressively driving operational improvements and structurally reducing supply chain costs. We are making steady progress in addressing production and supply chain challenges while delivering on our customer experience commitments."

    Ingredion also announced that its Board of Directors has authorized the repurchase of up to an additional 8 million shares of the Company's common stock from November 5, 2018 through December 31, 2023. Zallie said, "The Board's increased share repurchase authorization reflects its confidence in the Company's ability to generate strong cash flow from operations, support strategic investments, and fulfill its commitment to return capital to shareholders."

    *Adjusted diluted earnings per share ("adjusted EPS") is a non-GAAP financial measure. See the Supplemental Financial Information entitled "Non GAAP Information" included in this press release for a reconciliation of this non-GAAP financial measure to the most directly comparable U.S. GAAP measure.

    In 2018 through the third quarter, the Company repurchased 1.6 million shares.

    The Company expects its existing program authorized on December 12, 2014 for repurchase of up to five million shares of common stock to be substantially completed during the fourth quarter of this year.

    Repurchases under the stock repurchase program may be made by the Company from time to time in the open market, in privately negotiated transactions or otherwise, at prices that the Company deems appropriate. The stock repurchase program does not obligate Ingredion to repurchase any shares under the authorization, and the program may be suspended, discontinued or modified at any time, for any reason and without notice.

    The Company will release its 2018 third quarter financial results for the period ended September 30, 2018 before the market opens on Thursday, November 1, 2018 at 7:30 a.m. Central Time (8:30 a.m. Eastern Time).

    ABOUT THE COMPANY
    Ingredion Incorporated (NYSE: INGR) headquartered in the suburbs of Chicago, is a leading global ingredient solutions provider serving customers in more than 120 countries. With 2017 annual net sales of nearly $6 billion, the company turns grains, fruits, vegetables and other plant materials into value-added ingredients and biomaterial solutions for the food, beverage, paper and corrugating, brewing and other industries. With 27 Ingredion Idea Labs(R) innovation centers around the world and more than 11,000 employees, the Company develops ingredient solutions to meet consumers' evolving needs by making crackers crunchy, yogurt creamy, candy sweet, paper stronger, and adding fiber to nutrition bars. For more information, visit Ingredion.com.

    CONTACTS:
    Investors: Heather Kos, 708-551-2592
    Media: Becca Hary, 708-551-2602

    ###

    This announcement is distributed by West Corporation on behalf of West Corporation clients.
    The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
    Source: Ingredion Incorporated via Globenewswire

     
    Copyright 2018 ACN Newswire. All rights reserved. www.acnnewswire.com

    0 0

    ETERNUS DX8100 S4
    ETERNUS DX8900 S4
    TOKYO, Oct 24, 2018 - (JCN Newswire) - Fujitsu launches two new models in its Fujitsu Storage ETERNUS DX8000 S4 series of high-end storage systems, the ETERNUS DX8100 S4 and the ETERNUS DX8900 S4. Sales will commence today, October 24. The ETERNUS DX8900 S4 supports connections with open systems, such as mission-critical x86, UNIX, and x86 servers, providing performance approximately 1.3 times better than previous models. The system also reduces data storage capacity usage by about 50%(1) with newly deployed data compression technology. Both new models feature support for connections to Fujitsu mainframes from its Fujitsu Server GS21 series, supporting ICT infrastructure for key systems in the mission-critical field.
    Background

    In recent years, in the mission-critical field that supports society's infrastructure, including finance, transportation, and energy, there has been a demand for the creation of business in new areas utilizing ICT, such as fintech, smart cities, and smart grids. The ICT infrastructure supporting these efforts requires even higher performance and operational flexibility, including resource extension and the simultaneous high-speed processing of large volumes of data.
    Features of the New Models

    1. Designed to provide high performance

    The ETERNUS DX8900 S4 delivers performance of up to about 10 million IOPS, 1.3 times that of conventional models(2), in applications connected to open systems. This is due to the use of high performance CPUs in its storage controllers(3) and memory capacity about 3 times conventional models. In addition, cache response has been improved by installing NVMe(4) SSDs(5) capable of high response speeds as a secondary cache.

    2. Enabled to build low-cost system infrastructure

    In applications connected to open systems, the ETERNUS DX8900 S4 reduces data storage capacity usage by about 50% while limiting the impact on performance by incorporating a new dedicated chip to handle data compression processing in real time. This enables efficient operations that reduce the amount of storage media needed. With support for high-capacity SSDs of up to 30TB, this enables the building of low-cost system infrastructure.

    3. Provide highly reliable systems for mission-critical applications

    Both new models can be connected to Fujitsu's GS21 series of mainframes, which the company plans to continue to offer through 2030 and beyond. The new models therefor support the ICT infrastructure of core systems in the mission-critical field, where high reliability is needed. The ETERNUS DX8100 S4 is also available in an all-in-one format, incorporated into the storage unit within GS21 models, delivering a compact server structure that reduces installation space by up to 40% compared to conventional models.

    Availability

    The ETERNUS DX8100 S4 is only available in Japan. The ETERNUS DX8900 S4 is available worldwide. Both models are available from January 18, 2019.

    (1) Reducing data storage capacity usage by about 50% This is the average compression rate for general applications, not a guarantee of a 50% reduction.
    (2) Up to about 10 million IOPS, 1.3 times that of previous models Read and write performance in one second when reading 8KB of data in a random access format only. Compared against existing models in Fujitsu's ETERNUS DX8000 S3 series.
    (3) Storage controllers Computational processing unit that handles data reads and writes as well as the management and control of storage media.
    (4) NVMe Non-Volatile Memory Express. A logical device interface standard for connecting to non-volatile storage media through PCI Express (PCIe), a next-generation connection interface standard to replace SAS.
    (5) SSDs Solid state drives. Drives that use flash memory, a semiconductor-based storage element.

    About Fujitsu Ltd

    Fujitsu is the leading Japanese information and communication technology (ICT) company, offering a full range of technology products, solutions, and services. Approximately 140,000 Fujitsu people support customers in more than 100 countries. We use our experience and the power of ICT to shape the future of society with our customers. Fujitsu Limited (TSE: 6702) reported consolidated revenues of 4.1 trillion yen (US $39 billion) for the fiscal year ended March 31, 2018.

    For more information, please see www.fujitsu.com.
    This release at www.fujitsu.com/global/about/resources/news/press-releases/.

    Contact:
    Fujitsu Limited Public and Investor Relations Tel: +81-3-3215-5259 URL: www.fujitsu.com/global/news/contacts/

    Copyright 2018 JCN Newswire. All rights reserved. www.jcnnewswire.com

    0 0

    The Lexus ES, which launched the brand alongside our LS flagship, continues to deliver heightened comfort, craftsmanship, and luxury as it enters its 7th generation.

    TOKYO, Oct 24, 2018 - (JCN Newswire) - Lexus announced the start of 2019 Lexus ES sales at all its dealerships across Japan.

    Highlights:
    - Its head-turning profile reflects its dynamic capabilities and continues the brand's commitment to crafting vehicles with heightened excitement, emotion, and passion.
    - The GA-K platform provides the foundation for heightened comfort, quietness, and driving dynamics.
    - Lexus' signature driving feel is embodied in the new ES, making it even more exciting to drive under a variety of driving situations and road conditions.
    - The world's first production Digital Side-View Monitors and the latest in safety technology emphasize Lexus' commitment to safety.

    The ES was introduced in 1989 as part of Lexus' debut vehicle lineup alongside the brand's flagship model, the LS. Armed with unparalleled ride quality, quietness, and a spacious cabin, the ES helped establish the Lexus brand across the world, serving as the brand's core product in many countries and regions. Now, it is available in Japan for the very first time.

    As it enters its seventh-generation, the Lexus ES further enhances its world-renown ride comfort and driving dynamics all at the same time. Blending key elements of design and performance, the new ES will challenge the traditional expectations of consumers.

    Following in the path of the LC and LS flagship coupe and sedan, the ES is the latest expression of the new generation of Lexus vehicles, instituting a fresh era of design and performance.

    Built on the GA-K platform, which demonstrates high torsional rigidity and a low center of gravity, the all-new ES features a sleek and bold exterior, a spacious, plush interior, and exciting driving performance, all longstanding Lexus trademarks. The new platform/powertrain combination delivers flawless silky, smooth ride comfort, inheriting and further enhancing the DNA of past ES models. With sharp handling response and rock-solid stability, the ES exemplifies the Lexus"Yet" philosophy--the successful pairing of two contradictory ideas--with its "smooth, silky ride yet sharp handling."

    The ES comes equipped with the world's first production Digital Side-View Monitors, as well as the brand's innovative active safety package Lexus Safety System+. Utilizing the very latest in automotive safety technology offer drivers greater peace of mind and emphasizes the brand's strong commitment to safety.

    The all-new ES will be priced from Yen 5,800,000 to Yen 6,980,000 (tax included).(2)

    Main features of the all-new ES

    New generation Lexus designMajor changes to exterior and interior styling

    Exterior

    - Taking advantage of the GA-K platform's low center of gravity, the ES' low, wide exterior proportions mirror the way the sporty sedan performs on the road. With the slightly aft placement of the A-pillars and the revised angle of the rear pillars, Lexus designers have succeeded in creating a sleek, dynamic silhouette. With this new body shape, Lexus designers sought to produce a sportier car with class-leading aerodynamics, while maintaining the ES' customary spacious cabin. High-quality materials and fastidious attention to the smallest of styling details make the all-new ES the very example of functional beauty and high quality.
    - A more expressive face was achieved through combination of a new mesh pattern for Lexus' signature spindle grille, defined by a continuous flow of small "fin" shapes; the sharp, sculpted edges of the car's body, and newly designed headlamps with three compact LED lamps.
    - The rear design adopts Lexus' distinct personality traits, including the stable stance of the wide rear tires and combination tail lamps featuring three L-shaped lenses.
    - Two new colors are introduced: Ice Ecru Mica Metallic that emphasizes the car's elegant nature and Sunlight Green Mica Metallic, a gorgeous deep shade that affords the car dramatic presence.

    Interior

    - The all-new ES positions driver and passengers as the focal points of the interior. The cockpit seemingly cocoons the driver, facilitating a complete connection with the car and delivering a truly exhilarating driving experience. Passengers are enclosed in a comfortable, safe environment where they can relax and enjoy the ride.
    - The center console and armrest flow together in unity, while the upper/lower front seatbacks have been designed to allow easy operation of the controls and viewing of the monitor without necessitating a change in driver posture. The upper part of the seat, placement of the fully adjustable steering wheel, and strategic positioning of the foot pedals have been designed to achieve the optimal driving position. This and the lateral support provided by the seat were the result of vigorous testing and data gathering. The instrument panel and door trim meet in a seamless flow, creating a wide and spacious atmosphere in the cabin.
    - The rear passengers are also treated to an expansive atmosphere, in part due to the abundant legroom, as well as the enveloping nature of the interior layout, which produces a sense of safety. The seats themselves have been designed for maximum comfort and support, featuring rich materials and a new electric reclining feature.(4)
    - As an option, door armrest upholstery is offered in a material that incorporates Viscotecs TM(5) technology and features a three-dimensional pattern. This material is used throughout the cabin for an elegant feel and a sense of spaciousness.

    GA-K platform and 2.5-liter Lexus Hybrid Drive System help deliver the Lexus signature driving feel in the new ES

    With significantly enhanced supple ride quality that has been an integral part of the ES DNA, the new ES also exhibits a newfound sportiness that thoroughly captures the ideals of the new generation of Lexus. At the heart of the car's more athletic nature is the brand's latest driving technology, namely, the GA-K platform and new-generation hybrid system. After thoroughly analyzing human movements and responses, Lexus engineers have created a car that, as much as possible, serves as a natural extension to the driver's body. The engineers focused especially on precisely executing the driver's inputs, immediate vehicle response, and creating a comfortable cockpit.

    GA-K platform

    - In addition to demonstrating high rigidity and possessing a low center of gravity, the new Lexus platform features a double-wishbone rear-suspension setup with an optimal overall geometry that results in excellent handling and stability. The sharp response provided by the rack-mounted electric power steering system gives the new ES precise steering, part of Lexus' signature driving feel. The low placement of the driver's seat (low hip point), a fully adjustable steering wheel, and the strategic positioning of the pedals help promote the optimal seating position for the driver.
    - The front shock absorbers of models not featuring Adaptive Variable Suspension are equipped with a new ultra low-velocity valve in the piston that manages oil flow in response to the most minor of road irregularities and generates appropriate damping force. This swing valve shock absorber is a world-first.(1) Even when the stroke speed of the shock absorber is low, it will exert appropriate damping force, providing excellent responsiveness on all varieties of road surfaces, resulting in a consistently even ride quality.
    - To enhance the extremely quiet nature that has been an integral part of the ES' DNA, Lexus engineers adopted the highest levels of sound absorption, sound insulation, and noise-cancelling measures, including a flowing body shape that was developed through many hours of wind-tunnel testing. Additional features, such as noise reduction wheels and sound-insulting acoustic glass from the flagship LS sedan, have also been employed. Sound produced by the engine and audio system has been precisely tuned, resulting in cabin sounds set at a frequency most comfortable to the human ear.

    Lexus Hybrid Drive System

    - The 2.5-line inline-4 engine is equipped with laser-clad intake valve seats, which permit increased airflow into the cylinder and a new intake port shape that increases the tumble-flow turbulence of incoming air and fuel for high-speed combustion. The new engine achieves world-leading thermal efficiency, combining robust power delivery with excellent response to deliver superb fuel efficiency of 23.4 km/liter (under the JC08 test cycle).
    - The ES hybrid system achieves excellent fuel efficiency and powerful acceleration due to the new hybrid transaxle with improved efficient internal power flow and a higher-efficiency power control unit(6).
    - A new, more compact hybrid battery is located beneath the rear seats, contributing to ideal weight balance and low center of gravity, while enlarging cargo space.

    F SPORT

    - The F SPORT appearance and performance package is now available on the ES for the first time, providing sharper handling response and a more aggressive appearance. F SPORT enhances the ES' already excellent responses with new solenoid-type Adaptive Variable Suspension(7), which provides precise damping force in all driving situations, and performance dampers at the front and rear to further increase body rigidity. 19-inch alloy wheels with low-profile tires result in exceptional handling, high cornering stability, and a solid ride quality.
    F SPORT grille features a new F-mesh pattern, yielding a sportier front fascia.
    - Special sport seats hold the driver and passenger more firmly during spirited driving, while a custom steering wheel and instrument gauges give the interior more visual flair.
    - To convey the F SPORT's razor-sharp, on-road character to the interior, Lexus takumi craftsmen adorned the cabin with an exclusive aluminum ornamentation that undergoes a process called hadori, used in the finishing of samurai swords. By employing the latest polishing technologies, craftsmen were able to lend a distinct impression of traditional Japanese sword artistry throughout the interior of the ES F SPORT.

    Equipped with the latest in cutting-edge safety technology, including the world's first Digital Side-View Monitors

    Lexus remains committed to rapidly developing the top safety technologies in the world and equipping them into as many of its vehicles as possible. In addition to the world's first Digital Side-View Monitor, the ES is also equipped with the latest version of the Lexus Safety System+.

    - The new ES is the first production car in the world to offer a digital side-view monitor system. Digital Side-View Monitors use exterior cameras mounted on the front doors to transmit images to two 5-inch monitors inside the cabin at the base of each A-pillar. The cameras are resistant to raindrop stains, and because the monitors are located inside the vehicle, the driver always has a clear view of the transmitted image, no matter the weather. Replacing conventional mirrors with small cameras gives the driver virtually unblocked forward views out the side windows, and wind noise is significantly reduced, resulting in a quiet cabin.
    - The Lexus Safety System+ featured in the new ES is thoroughly updated with the latest technology. A forward-looking camera and millimeter-wave radar remain integral parts of the safety package to further reduce road fatalities and traffic accidents, while easing the burden and stress on the driver. With this system, the new ES offers the highest level of security, allowing the driver to enjoy a safe, pleasant motoring experience.

    Main Features of Lexus Safety System+

    - Pre-Collision System uses an in-vehicle camera and front-grille-mounted millimeter-wave radar to help spot bicyclists and pedestrians during low-light conditions.
    - Dynamic Radar Cruise Control together with Lane Tracing Assist (LTA) help ensure the new ES stays in its own lane. If the system detects a potential lane departure while Dynamic Radar Cruise Control is activated, LTA alerts the driver with a visual warning and either an audible alert or steering wheel vibration; it may also apply a small active steering correction.
    - The Adaptive High Beam System (AHS(8)) automatically controls light intensity to safeguard oncoming vehicles or those in front of the ES from glare.
    - Road Side Assist (RSA(9)) acquires road sign data via a camera and the navigation system, and displays information using the head-up display and multi-information display, thus reducing driver failure to recognize signs and support safe driving.
    - The Parking Support Brake System eases burden when parking and tight maneuvering is carried out in restricted spaces such as parking lots, where moving vehicles and pedestrians are likely to be present. The system detects pedestrians using a rear camera, and in case of a possible collision, helps to mitigate damage through use of alerts and active brake control.
    - The Panoramic View Monitor provides a bird's-eye view of the surrounding environment, equipping drivers with a composite image of the vehicle's surroundings.

    (1) As of October in 2018.
    (2) Manufacturer's Suggested Retail Price. Recycling fee not included.
    (3) Standard for F SPORT, "Version L." Options for Standard specifications.
    (4) Standard for "Version L"
    (5) Standard for "Version L." ViscotecsTM is a registered trademark of Seiren Co. Ltd.
    (6) PCU Power Control Unit
    (7) AVS Adaptive Variable Suspension System
    (8) AHS Adaptive High-beam System
    (9) RSA Road Sign Assist
    (10) Parking Support Brake (for pedestrians in the rear) is standard for "version L."

    About LEXUS

    Since its debut in 1989, Lexus has earned a worldwide reputation for high-quality products and exemplary customer service. Lexus is the hybrid leader among luxury brands, offering hybrids that provide the best in innovative technology and premier luxury. The evolution of Lexus is reflected in the progressive designs of its new vehicles. The grille, dynamic light treatments, and sculptured lines create a distinctive look of luxury for Lexus. For more information, please visit www.lexus-int.com and www.lexus-int.com/news/.

    Contact:
    Public Affairs Division Global Communications Department Toyota Motor Corporation Tel: +81-3-3817-9926

    Copyright 2018 JCN Newswire. All rights reserved. www.jcnnewswire.com

    0 0

    Photo 1: (From left to right) Professor Yang Bin (Vice President of Tsinghua University), Dr Lui Che-woo (Chairman of K. Wah Group and Director of LUI Che Woo Charity), and Professor Chen Xu (Chancellor of Tsinghua University)
    Photo 2: Professor Chen Xu, Chancellor of Tsinghua University (right) presented a certificate of donation to Dr Lui Che-woo (left) as a token of thanks to his generous donations to Tsinghua University
    Forum held to share the idea of inclusivity in diversity with teachers and students

    BEIJING, Oct 25, 2018 - (ACN Newswire) - Dr Lui Che-woo, Chairman of K. Wah Group and Director of LUI Che Woo Charity, announced the donation of RMB200 million to Tsinghua University to fund the construction of two new blocks at the Tsinghua University Biomedical Sciences Building, which are set to provide better research and teaching facilities for the faculties and students, as well as support the development of medical, pharmaceutical science and other related disciplines of Tsinghua University. To recognize Dr Lui for his enthusiasm and contributions to the development of Tsinghua University, the new blocks are named "Lui Che Woo Building".

    The signing ceremony for Lui Che Woo Building of the Tsinghua University Biomedical Sciences Building was held at Tsinghua University in Beijing today. Professor Chen Xu, Chancellor and Professor Yang Bin, Vice President, signed the donation agreement with Dr Lui on behalf of Tsinghua University and Tsinghua University Education Foundation respectively. Dr Lui was presented with a donation certificate as a token of appreciation and commendation of his donations and ardent support for scientific research in biomedical science.

    Dr Lui revealed the reasons for making this donation in his speech, "Tsinghua University's commitment to nurturing top-class talents with global vision, social consciousness and becoming a world-class university, as well as its motto of 'nurturing virtues and personal growth' are in perfect tandem with my own convictions in education, hence the decision to support the development of the Biomedical Sciences Building. Tsinghua University's School of Life Sciences, School of Medicine and School of Pharmaceutical Sciences are the top frontier research academic institutions in China, so I hope this donation will encourage academic research in and applications of innovative scientific technologies, thereby bolstering our nation's soft strengths."

    Mr Zhang Xiaoming, Director of the Hong Kong and Macao Affairs Office of the State Council, Mr Qiao Xiaoyang, Former Deputy Secretary-General of the Standing Committee of the National People's Congress, Ms Yu Jianming, Deputy Director of the Central United Front Work Department, the Overseas Chinese Affairs Office of the State Council, Ms Qiu Wei, Deputy Director of the Central United Front Work Department, the Hong Kong, Macao and Taiwan Affairs Bureau, Mr Hu Zhengyue, former Commissioner of Office of the Commissioner of the Ministry of Foreign Affairs of the People's Republic of China in the Macao SAR, Mr Wang Lianduan, Executive Deputy Director of Bureau No. 1 of The National Committee of the Chinese People's Political Consultative Conference, Mr Liu Wenda, Deputy Director of Department of Liaison of the Hong Kong and Macao Affairs Office of the State Council, Mr Qu Chaoqun, Deputy Director of the Central United Front Work Department, the Hong Kong, Macao and Taiwan Affairs Bureau, Mrs Lui Chiu Kam Ping, Ms Paddy Lui, Executive Director of K. Wah International Holdings Limited, Professor Chen Yinghua, Secretary of School Committee of Communist Party of China, School of Life Sciences, Professor Wang Xinquan, Deputy Dean of School of Life Sciences, Professor Hong Bo, Secretary of School Committee of Communist Party of China, School of Medicine, Professor Zhang Jingren, Deputy Dean of School of Medicine, Professor Liu Qingfei, Secretary of School Committee of Communist Party of China, School of Pharmaceutical Sciences, Ms Yuan Wei, Secretary General of Tsinghua University Education Foundation, Mr Li Bing, Vice Secretary General of Tsinghua University Education Foundation and members of the senior management of K. Wah Group were joined by 150 faculty members and students of Tsinghua University to witness this important moment.

    Professor Chen Xu, Chancellor of Tsinghua University, expressed that, "Dr Lui generously supports our university in building new medical science building - 'Lui Che Woo Building', which fully reflects his dedication in education and deep affection for Tsinghua. I believe that the 'Lui Che Woo Building' will definitely lay an important foundation and further equip Tsinghua to becoming world-class university in medicine."

    Following the signing ceremony, Dr Lui joined a symposium with Professor Yang Bin, Vice President of Tsinghua University, hosted by Professor Long Denggao, Director of the Centre for Chinese Entrepreneur Studies. Dr Lui told the story of his business venture and shared the idea of inclusivity in diversity with faculty members and students. He shared the beliefs and insights behind the establishment of the international award, "LUI Che Woo Prize - Prize for World Civilisation". He encouraged the students to pay more attention to current world issues and promote sustainable development with a global mindset. Dr Lui answered some of the questions raised by Tsinghua students and the symposium ended in the warm applause from the audience with student representative presented flowers to Dr Lui.

    Dr Lui has always been a passionate benefactor for the development of biomedicine and education. In 2015, he founded the "LUI Che Woo Prize - Prize for World Civilisation" in Hong Kong as an annual, first of its kind international cross-sector innovative award for advancing world civilization and inspiring people to build a more harmonious world. It aims to recognize and honour individuals or organization all over the world for outstanding contributions and encourages the continuation of that work in promoting sustainable development of the world, betterment of the welfare of mankind and positive life attitude and positive energy. Mr Xie Zhenhua, Tsinghua University alumni and Vice Chairman of the Committee of Population, Resources and Environment of the Chinese People's Political Consultative Conference who was awarded the "Sustainability Prize" in the "LUI Che Woo Prize - Prize for World Civilisation" in 2017, donated full amount of the cash award to Tsinghua University to set up the "Global Climate Governance and Green Development Fund", supporting international cooperation in low-carbon development and climate governance, develop related projects and provide scholarships, in a full effort to drive initiatives in the prevention of climate changes and general climate governance.

    The planned Biomedical Sciences Building will be mainly used by the School of Life Sciences for teaching and scientific research in life sciences, medicine, pharmaceutical sciences and other cross-disciplinary subjects. It will also house top scientific research institutions including Beijing Advanced Innovation Centre for Structural Biology, McGovern Institute for Brain Research and National Centre for Protein Science. Lui Che Woo Building, comprising Blocks C and D, is intended to provide the venue for teaching and scientific research in pharmaceutical sciences developments and cross-disciplinary subjects in life sciences, while housing scientific research institutions such as Global Health Drug Discovery Institute (Beijing), Tsinghua Pharmaceutical Innovation Centre and Institute for Stem Cell Biology and Regenerative Medicine.

    Photo1
    https://www.acnnewswire.com/topimg/Low_KWah20181025-1.jpg
    (From left to right) Professor Yang Bin (Vice President of Tsinghua University), Dr Lui Che-woo (Chairman of K. Wah Group and Director of LUI Che Woo Charity), and Professor Chen Xu (Chancellor of Tsinghua University)

    Photo2
    https://www.acnnewswire.com/topimg/Low_KWah20181025-2.jpg
    Photo 2: Professor Chen Xu, Chancellor of Tsinghua University (right) presented a certificate of donation to Dr Lui Che-woo (left) as a token of thanks to his generous donations to Tsinghua University

    Photo3
    https://www.acnnewswire.com/topimg/Low_KWah20181025-3.jpg
    Dr Lui Che-woo, Chairman of K. Wah Group and Director of LUI Che Woo Charity (fourth from left), Mr Zhang Xiaoming, Director of the Hong Kong and Macao Affairs Office of the State Council (second from left), Mr Qiao Xiaoyang, Former Deputy Secretary-General of the Standing Committee of the National People's Congress (fifth from left), Ms Qiu Wei, Deputy Director of the Central United Front Work Department, the Hong Kong, Macao and Taiwan Affairs Bureau (fourth from right), Mr Wang Lianduan, Executive Deputy Director of Bureau No. 1 of The National Committee of the Chinese People's Political Consultative Conference (third from right), Mrs Lui Chiu Kam Ping (third from left), Ms Paddy Lui, Executive Director of K. Wah International Holdings Limited (second from right), Professor Chen Xu, Chancellor of Tsinghua University (fifth from right) and Mrs Millie Lui (first from left)

    About K. Wah Group
    K. Wah Group was founded in 1955 by Dr Lui Che-woo, who transformed the company into a multinational corporation. Core businesses include property development and investment, entertainment and leisure resorts, hospitality and construction materials. The Group has a business presence in Mainland China, Hong Kong, Macau, Southeast Asia and major cities in the US. The Group includes two Hong Kong-listed flagships: K. Wah International Holdings Limited ("KWIH"; HK stock code: 00173) and Galaxy Entertainment Group Limited ("GEG"; HK stock code: 00027 and a member of the Hang Seng Index). Other major subsidiaries include Stanford Hotels International and K. Wah Construction Materials Limited and, in the US, Stanford Hotels Corporation and Cresleigh Homes. To date, the Group has over 200 subsidiaries and close to 30,000 staff worldwide.

    Website: http://www.kwah.com

    Media Enquires:
    K. Wah International Holdings Limited
    Rita Lai Tel: (852) 2960 3386 Email: ritalai@kwah.com
    Catherine Lee Tel: (852) 2880 8220 Email: catherinelee@kwah.com
    Cynthia Lee Tel: (852) 2880 1869 Email: cynthialee@kwah.com
    Fax: (852) 2811 9710

    Strategic Financial Relations Limited
    Maggie Au Tel: (852) 2864 4815 Email: maggie.au@sprg.com.hk
    Patty Yeung Tel: (852) 2114 4990 Email: patty.yeung@sprg.com.hk
    Fax: (852) 2527 1196



     
    Copyright 2018 ACN Newswire. All rights reserved. www.acnnewswire.com

    0 0

    HONG KONG, Oct 25, 2018 - (ACN Newswire) - Ausnutria Dairy Corporation Ltd ("Ausnutria" or the "Company", together with its subsidiaries, the "Group"; stock code: 1717.HK), a company engages in the research and development, production and distribution of all dairy products (including infant formula) and nutrition products with production facilities principally based in the Netherlands, Australia, New Zealand and the PRC, is pleased to announce that the issue of 249,000,000 new shares to CITIC Agri Fund Management Co., Ltd. ("CITIC Agri Fund") is officially completed today.

    During the course of the 15-year development of Ausnutria, CITIC Agri Fund expresses its high recognition towards Ausnutria through investing in the Company. The presence of CITIC Agri Fund strengthens Ausnutria's shareholder background and financial resources. The total consideration for the issue of 249,000,000 new shares to CITIC Agri Fund is HK$1,289,820,000. CITIC Agri Fund is interested in 23.97% of the total number of Shares and replaces Center Laboratories, Inc. and its subsidiaries as the single largest shareholder of the Company. Center Lab and its subsidiaries will be holding approximately 23.78% of the Shares and remain as one of the substantial Shareholders of the Company.

    Mr. Yan Weibin, Chairman and Executive Director of the Group, said "the Company is inspired to successfully complete the issue of new shares and introduce CITIC Agri Fund to become the single largest shareholder of the Company. As one of the leaders in the dairy industry, the Company will abide by commitments, keep eyes on the target, strive to provide perfect products and services, respond to market uncertainty with firm strategies, and head towards the 'Golden Decade' of Ausnutria through three steps to achieve steady and rapid development of the Company. The Company will not let down the deep affection of CITIC Agri Fund, nor fail to the trust of all shareholders and communities. At present, the progresses of global supply chain layout deployment and global team building have been completed, with the ability of research and development and market distribution in place. Our goat milk formula products have basically been in the lead wordwidely, also our cow milk formula taken the forehand position in the PRC maket. Multiple for projects of corporate development have been progressed smoothly. All colleagues are united to achieve in the same goal. With the support of consumers and communities, the Company is confident to realize the great vision of "Becoming the World's Most Trusted Formula and Nutrition Health Company".

    About Ausnutria Dairy Corporation Ltd.
    Ausnutria Dairy Corporation Ltd is a leading infant milk formula company with production facilities principally based in the Netherlands, Australia, New Zealand, and the PRC The Company is engaged in the worldwide research, production and sales of infant formula, adult milk and other dairy and nutrition products. It owns several famous infant formula and milk powder brands, including "Kabrita", "Allnutria" and "Hyproca". Ausnutria's factories in the PRC were among that first batch of factories that had been granted with the National Infant Formula Enterprise Production Permit. The factory in the Netherlands is also one of the first infant milk formula manufacturers to obtain import licenses for overseas products under the new policy in the PRC.


     
    Copyright 2018 ACN Newswire. All rights reserved. www.acnnewswire.com

    0 0

    - Tenant sales and footfall in URW's European shopping centres up by +2.3% (+3.6% for Flagships) and +2.0%, respectively; US specialty sales per sq. ft up by +5.5% (+5.6% for Flagships);
    - More than 55% of the EUR3 Bn disposal programme announced in December 2017 achieved already;
    - URW expects the Adjusted Recurring Earnings per Share for 2018 in the range of EUR12.75 - EUR12.90

    Paris, Amsterdam, Oct 26, 2018 - (ACN Newswire) - Financial information as at September 30, 2018

    1. Turnover

    The proportionate turnover of Unibail-Rodamco-Westfield ("URW" or the "Group") for the first nine months of 2018 amounted to EUR2,164.3 Mn, up +37.9% mainly due to acquisition of Westfield Corporation ("WFD") by Unibail-Rodamco ("UR").

    https://bit.ly/2D1Zuh7

    2. Gross Rental Income

    The proportionate Gross Rental Income (GRI) of the Shopping Centre division amounted to EUR1,605.3 Mn for the first nine months of 2018, an increase of +40.2% (+3.6% on UR's perimeter prior to the acquisition of WFD). The Continental European rental growth was partially offset by the impact of the disposal of non-core shopping centres in the Nordics (Eurostop Arlanda, Arninge Centrum and Eurostop Orebro) in 2017 and in Spain (Bahia Sur, Vallsur, El Faro and Los Arcos) in 2018. The performance of Central Europe was boosted by the delivery of Wroclavia, the extension of Centrum Chodov, and the acquisition of Metropole Zlicin in 2017. GRI from the US and UK reflects the contribution from WFD since June 2018.

    The GRI of the Office division amounted to EUR115.5 Mn, up by +2.9% compared to the first nine months of 2017. The rental income of offices in France decreased by -0.7%, due to the disposal of the So Ouest Plaza office building in 2017.

    The GRI of the Convention & Exhibition division increased by +6.8% to EUR148.0 Mn due to the triennial Intermat exhibition and the opening of Pavilion 7 in Porte de Versailles.

    https://bit.ly/2PqhSWs

    Major events

    1. Tenant sales and footfall

    Tenant sales(1) through September 30, 2018, in the Group's European shopping centres(2) were up by +2.3% for the Group and +3.6% for Flagships(3) compared to the same period in 2017, with strong performance in Central Europe, France and the Nordics.

    For the US, specialty sales per sq. ft(4) for the period through September 30 were up by +5.5% on a trailing 12-month basis.

    Through August, tenant sales in Europe (+2.4%) outperformed the aggregate national sales indices(5) (which for a number of the Group's regions include online sales) by +186 bps, reflecting the superior quality and appeal of the Group's European shopping centres. In France, tenant sales through August outperformed the IFLS(6) and CNCC(7) indices by +343 and +493 bps, respectively.

    Footfall(8) in European shopping centres grew by +2.0% through Q3-2018. The UK, France, the Nordics and Central Europe all posted strong footfall growth of +4.6%, +3.8%, +3.6% and +3.4%, respectively.

    While overall tenant sales growth in the Group's shopping centres was solid, some retailers are facing significant challenges in dealing with the changing retail environment. Many focus carefully on all elements of their business, including new store openings. Consequently, negotiations on lease terms are generally taking longer.

    2. Post-closing events

    On October 15, 2018, URW entered into an agreement with Singapore's sovereign wealth fund GIC for the sale of Tour Ariane in La Defense. The net disposal price ("NDP") of EUR464.9 Mn represents a premium to the book value as at June 30, 2018.

    Together with the disposals announced earlier this year, the Group has now disposed or entered into agreements to dispose of a total of 8 assets(9) representing a total acquisition cost of EUR1,920 Mn, a blended net initial yield of 4.5% and a weighted average premium of +8.1% to their book value as at June 30, 2018. The NDP to URW of these disposals is expected to amount to EUR1,787 Mn. More than 55% of the approximately EUR3 Bn European disposal programme to be accomplished over the next several years announced on December 12, 2017, has already been agreed or completed since June 30, 2018.

    3. Outlook

    The closing of the WFD acquisition on June 7, 2018, and the impact of the cost synergies realized through June 30 will be accretive for the year 2018. Allowing for the impact of the accelerated disposals, with almost EUR1.8 Bn already agreed or completed YTD (-11 cents), and the shift of the recognition of development profits (timing differences) on projects in London and California (-17 cents), the Group expects its Adjusted Recurring Earnings per Share to be in the range of EUR12.75 - EUR12.90.

    4. Financial schedule

    The next financial events on the Group's calendar will be:

    February 13, 2019: 2018 Full-Year results, 2019 guidance and medium-term outlook (after market close)
    March 29, 2019: Interim dividend
    April 24, 2019: 2019 1st quarter results (after market close)
    May 17, 2019: AGM Unibail-Rodamco SE
    June 13 & 14, 2019: Investor Days
    July 5, 2019: Final dividend, subject to approval by the AGMs of Unibail-Rodamco SE and WFD Unibail-Rodamco N.V.

    For further information, please contact:
    Investor Relations
    Samuel Warwood
    Maarten Otte
    +33 1 76 77 58 02
    Maarten.otte@urw.com

    Media Relations
    Tiphaine Bannelier-Suderie
    D: +33 1 76 77 57 94
    Tiphaine.Bannelier-Suderie@urw.com

    About Unibail-Rodamco-Westfield

    Unibail-Rodamco-Westfield is the premier global developer and operator of flagship shopping destinations, with a portfolio valued at EUR63.7 Bn as at June 30, 2018, of which 86% in retail, 8% in offices, 5% in convention & exhibition venues and 1% in services. Currently, the Group owns and operates 97 shopping centres, including 56 flagships in the most dynamic cities in Europe and the United States. Its centres welcome 1.2 billion visits per year. Present on 2 continents and in 13 countries, Unibail-Rodamco-Westfield provides a unique platform for retailers and brand events, and offers an exceptional and constantly renewed experience for customers.

    With the support of its 3,700 professionals and an unparalleled track-record and know-how, Unibail-Rodamco-Westfield is ideally positioned to generate superior value and develop world-class projects. The Group has the largest development pipeline in the industry, worth EUR12.5 Bn.

    Unibail-Rodamco-Westfield distinguishes itself by its Better Places 2030 agenda, that sets its ambition to create better places that respect the highest environmental standards and contribute to better cities.

    Unibail-Rodamco-Westfield stapled shares are listed on Euronext Amsterdam and Euronext Paris (Euronext ticker: URW), with a secondary listing in Australia through Chess Depositary Interests. The Group benefits from an A rating from Standard & Poor's and from an A2 rating from Moody's.

    For more information, please visit www.urw.com
    Visit our Media Library at https://www.mediacentre.urw.com

    20181025 URW PR - Q3 2018: http://hugin.info/136618/R/2222272/870226.pdf

     
    Copyright 2018 ACN Newswire. All rights reserved. www.acnnewswire.com

    0 0

    At the 2018 Clinical Trials on Alzheimer's Disease (CTAD) Conference

    TOKYO, Oct 26, 2018 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced that Eisai presented the latest data from the Phase II clinical study (Study 201) of BAN2401, an anti-amyloid beta protofibril antibody, in 856 patients with early Alzheimer's disease, at a symposium session titled "Clinical and Biomarker Updates from BAN2401 Study 201 in Early Alzheimer's Disease" held on October 25 at the 11th Clinical Trials on Alzheimer's Disease (CTAD) conference in Barcelona, Spain.

    Study 201 is a placebo-controlled, double-blind, parallel-group, randomized study in 856 patients with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) or mild Alzheimer's dementia (collectively known as early Alzheimer's disease) with confirmed amyloid pathology in the brain. Patients were randomized to five dose regimens, 2.5 mg/kg bi-weekly, 5 mg/kg monthly, 5 mg/kg bi-weekly, 10 mg/kg monthly and 10 mg/kg bi-weekly, or placebo. This study used a Bayesian Adaptive Randomization Design to automatically allocate newly enrolled patients into the study to treatment arms showing higher probability of efficacy based on the results of interim analyses. The 10 mg/kg monthly and 10 mg/kg bi-weekly doses were determined to have greater efficacy, and as a result, the proportion of patients allocated to those treatment arms was greater.

    Conventional statistical methods on predefined clinical outcomes at the 18 month final efficacy time point included Alzheimer's Disease Composite Score (ADCOMS), Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog), and Clinical Dementia Rating Sum of Boxes (CDR-SB).

    The most current data presented at CTAD 2018 highlight topline results, originally presented by Eisai in July at the Alzheimer's Association International Conference (AAIC) 2018, as well as new data from pre-specified subgroup analyses and cerebrospinal fluid (CSF) biomarkers. The full CTAD presentation is available on the Investor Relations section of the Eisai website.

    From conventional statistical analysis of the topline results, the highest treatment dose demonstrated a statistically significant reduction in brain amyloid measured by positron emission tomography (PET) at 18 months (p
    A request from a health authority in July 2014 required an amendment to be implemented restricting enrollment of APOE4 carriers in the highest treatment dose arm (10 mg/kg bi-weekly), resulting in an imbalance of APOE4 carriers in that arm versus placebo. To assess the influence of APOE4 status on the observed effect in the highest treatment dose, the rates of clinical decline for APOE4 carriers and non-carriers in the placebo group were analyzed and shown not to be statistically significantly different from each other on ADCOMS, ADAS-Cog and CDR-SB. Analysis on clinical outcome measures was also conducted in pre-specified subgroups of APOE4 status. At the highest treatment dose, APOE4 carriers treated with BAN2401 saw 63% less decline in disease progression, while non-carriers saw 7% less decline, as measured by ADCOMS versus placebo at 18 months. These results suggest that the treatment effect for the 10 mg/kg bi-weekly dose is related to treatment with BAN2401 and not due to an imbalance in subject allocation by APOE4 status. In addition, the pooled 10 mg/kg bi-weekly and 10 mg/kg monthly doses result in less decline on ADCOMS versus placebo at 18 months (overall; 21%, APOE4 carriers; 25%, APOE4 non-carriers; 6%). More detailed results were presented at CTAD.
    Analyses of clinical outcome measures on pre-specified subgroups, by clinical stage and by use of concomitant Alzheimer's disease medications, were also conducted. Treatment with the highest treatment dose also resulted in less decline in disease progression on ADCOMS at 18 months versus placebo across subgroups of clinical stage (MCI due to AD subgroup; 33% and mild AD subgroup; 35%) and use of concomitant Alzheimer's disease medications (with concomitant AD meds; 23% and without concomitant AD meds; 41%). The study was not powered to show statistical significance in subgroups.

    Exploratory data on CSF biomarkers of neurodegeneration that are elevated in AD were also presented by Eisai. To increase the sample size of the CSF subgroup, analyses were conducted on samples from the combined 10 mg/kg bi-weekly and 10 mg/kg monthly cohorts. From the results, markers of synaptic damage (neurogranin), tau pathology (phosphorylated-tau, p-Tau), and axonal degeneration (neurofilament light chain, NFL) showed trends that are suggestive of impact on underlying disease pathophysiology.

    BAN2401 demonstrated an acceptable tolerability profile through 18 months of study drug administration. The most common treatment emergent adverse events were infusion-related reactions and amyloid-related imaging abnormalities (ARIA), both of which were dose-dependent. Incidence of ARIA-E (edema) was greater in APOE4 carriers. Ten percent of ARIA-E cases (5 of 48 patients) were symptomatic and included headache, visual disturbances, and confusion. Sixty percent of ARIA-E occurred within the first three months of treatment and approximately 89 percent of cases were mild to moderate in severity.

    Eisai and Biogen are currently discussing the next steps for BAN2401 with regulatory authorities. An open-label extension for patients previously enrolled in Study 201 is being planned, with enrollment expected to begin this year.

    This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that any investigational uses of such product will successfully complete clinical development or gain health authority approval.

    About BAN2401

    BAN2401 is a humanized monoclonal antibody for Alzheimer's disease that is the result of a strategic research alliance between Eisai and BioArctic. BAN2401 selectively binds to neutralize and eliminate soluble, toxic Abeta aggregates that are thought to contribute to the neurodegenerative process in Alzheimer's disease. As such, BAN2401 may have the potential to have an effect on disease pathology and to slow down the progression of the disease. Eisai obtained the global rights to study, develop, manufacture and market BAN2401 for the treatment of Alzheimer's disease pursuant to an agreement concluded with BioArctic in December 2007. In March 2014 Eisai and Biogen entered into a joint development and commercialization agreement for BAN2401 and the parties amended that agreement in October 2017.

    About Study 201

    Study 201 is a placebo-controlled, double-blind, parallel-group, randomized Phase II clinical study in 856 patients with mild cognitive impairment (MCI) due to Alzheimer's disease or mild Alzheimer's dementia (collectively known as early Alzheimer's disease) with confirmed amyloid pathology in the brain. This study used Bayesian Adaptive Randomization Design to automatically allocate newly enrolled patients into the study to treatment arms showing higher probability of efficacy based on the results of interim analyses. The study design included five dose regimens and placebo, and considered the efficacy of BAN2401 as well as dose responsiveness through 16 interim analyses that assessed potential for early success, an analysis based on ADCOMS at 12 months (primary endpoint), and a comprehensive final analysis at 18 months (secondary endpoints). Patients who received treatment with BAN2401 were randomized to five dose regimens, 2.5 mg/kg biweekly (52 patients), 5 mg/kg monthly (51 patients), 5 mg/kg biweekly (92 patients), 10 mg/kg monthly (253 patients), or 10 mg/kg biweekly (161 patients). Biomarker endpoints included changes in Abeta accumulated in the brain as measured by amyloid PET (positron emission tomography) as well as in cerebrospinal fluid (CSF), while ADCOMS (Alzheimer's Disease Composite Score), Clinical Dementia Rating Sum of Boxes (CDR-SB) and Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS- Cog) were measured as efficacy endpoints (clinical).

    About ADCOMS

    Developed by Eisai, ADCOMS (AD Composite Score) combines items from the ADAS-Cog (Alzheimer's Disease Assessment Scale-cognitive subscale), CDR-SB (Clinical Dementia Rating Sum of Boxes) and the MMSE (Mini-Mental State Examination) scales to enable a sensitive detection of changes in clinical functions of early AD symptoms and changes in memory. This Study 201 utilizes ADCOMS as its key endpoint for assessing clinical symptoms.

    About Amyloid PET Imaging

    Amyloid PET (Positron Emission Tomography) imaging is a diagnostic method that enables the visualization of amyloid plaque present in the brain as well as the quantitative evaluation of amyloid plaque distribution and accumulation in the brain via administration of a minute amount of PET tracer, which specifically binds to amyloid plaque. Amyloid PET imaging enables the assessment of pathology change and assistance of diagnosis of patients with Alzheimer's disease, including MCI due to AD, and could predict clinical response.

    About Correlation Coefficient

    The correlation coefficient indicates the strength of the relationship between two variables from two quantitative data distributions. The correlation coefficient ranges in value from -1 to 1, and as it approaches the absolute value of 1, it indicates a total positive linear correlation. In general, if a correlation coefficient is 0.6 or greater, it suggests there is a relationship between the variables.

    About the Joint Development Agreement between Eisai and Biogen for Alzheimer's Disease

    Eisai and Biogen are widely collaborating on the joint development and commercialization of Alzheimer's disease treatments. Eisai serves as the lead in the co-development of elenbecestat, a BACE inhibitor, and BAN2401, an anti-amyloid beta (Abeta) protofibril antibody, while Biogen serves as the lead for co-development of aducanumab, Biogen's investigational anti-amyloid beta (Abeta) antibody for patients with Alzheimer's disease, and the companies plan to pursue marketing authorizations for the three compounds worldwide. If approved, the companies will also co-promote the products in major markets, such as the United States, the European Union and Japan.

    As to BAN2401 and elenbecestat, both companies will equally split overall costs, including research and development expenses. Eisai will book all sales for elenbecestat and BAN2401 following marketing approval and launch, and profits will be equally shared between the companies.

    About Biogen

    At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. One of the world's first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp, and today has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy and is focused on advancing neuroscience research programs in Alzheimer's disease and dementia, multiple sclerosis and neuroimmunology, movement disorders, neuromuscular disorders, pain, ophthalmology, neuropsychiatry and acute neurology. Biogen also manufactures and commercializes biosimilars of advanced biologics.

    We routinely post information that may be important to investors on our website at www.biogen.com. To learn more, please visit www.biogen.com and follow us on social media - Twitter, LinkedIn, Facebook, YouTube.

    About BioArctic AB

    BioArctic AB (publ) is a Swedish research-based biopharma company focusing on disease modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. The company also develops a potential treatment for Complete Spinal Cord Injury. BioArctic focuses on innovative treatments in areas with high unmet medical needs. The company was founded in 2003 based on innovative research from Uppsala University, Sweden. Collaborations with universities are of great importance to the company together with our strategically important global partners in the Alzheimer (Eisai) and Parkinson (AbbVie) projects. The project portfolio is a combination of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market- and out-licensing potential. BioArctic's B-share is listed on Nasdaq Stockholm Mid Cap (STO:BIOA B). www.bioarctic.com.

    About Eisai

    Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our human health care philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Oncology and Neurology.

    As a global pharmaceutical company, our mission extends to patients around the world through our investment and participation in partnership-based initiatives to improve access to medicines in developing and emerging countries.

    For more information about Eisai Co., Ltd., please visit www.eisai.com.

    Contact:
    Biogen Inc. Public Affairs TEL: +1-781-464-3260 public.affairs@biogen.com Eisai Co., Ltd. Public Relations Department TEL: +81-(0)3-3817-5120 Eisai Inc. Public Relations Department TEL: +1-201-746-2139

    Copyright 2018 JCN Newswire. All rights reserved. www.jcnnewswire.com

    0 0

    HONG KONG, Oct 26, 2018 - (ACN Newswire) - YOVO, the world's first blockchain-powered mobile network and Blockpass, a data secure user identity and compliance solution, announced today their groundbreaking new partnership, set to transform the way we communicate. Together, the two companies want to make it possible to sign up for mobile phone service from anywhere, at any time, all while ensuring full data security for the user.

    YOVO is a mobile network built on the Stellar blockchain that is committed to openness, fairness, and transparency. As a company, YOVO builds privacy into everything they do. YOVO offers a range of innovative SIM-based mobile products and with YOVO Pay, it is also possible for users to pay for their current mobile service in cryptocurrency (in any of over 130 countries), without having to change their network or SIM. What's more, the next generation YOVO GO service makes it possible to have up to four extra numbers on a single device with a virtual SIM.

    Blockpass is digital identity application and service which brings control back to the user. Blockpass provides a streamlined and cost-effective user onboarding process for regulated industries and any kind of online service. From the Blockpass application, users can create, store, and manage, data-secure digital identity that can be used for an entire ecosystem of services or token purchase.

    Integration of YOVO and Blockpass will make signing up for mobile service faster and more secure than it has ever been before. It will only take a few moments for new users to start using YOVO services. YOVO users can then be sure that they are in full control of their own personal information.

    "We are committed to driving adoption of blockchain, and mobility is the perfect channel to reach just about everyone on the planet," said Richard Skaife, CEO and Co-Founder at YOVO. "Your smartphone is easily the most valuable device in your life and our partnership with Blockpass ensures it is protected from many of the known security and identity issues that mobile users face."

    "YOVO is a really exciting partnership for Blockpass," said Blockpass CEO Adam Vaziri. "The addition of a mobile network is unlike any other partner we have added to our ecosystem to date and brings very exciting possibilities to our network."

    The partnership comes after Blockpass announced last week that token-trading platform Ethfinex would integrate its solution as part of their standard compliant ICO solution. Blockpass also launched a world-first advanced blockchain identity research laboratory, the Blockpass Identity Lab at the end of September in collaboration with Edinburgh Napier University.

    About YOVO
    YOVO is the mobile network on the blockchain. Live in 130 plus countries with its YOVO Pay service. YOVO is due to bring a range of physical SIM, virtual SIM and eSim products into the market over the following months. YOVO uses blockchain as a way of returning the value you create back to you. This allows you to reduce your mobile service access costs. For more information: www.yovo.io

    About Blockpass IDN
    The goal of Blockpass IDN (http://www.blockpass.org/) is global realization of identity for the Internet of Everything. Through the use of blockchain technology and smart contracts, Blockpass is a production ready Regtech platform offering shared regulatory and compliance services for humans, businesses, objects and devices. As this identity system supports verification of humans (KYC), objects (KYO) and connected devices (KYD), it will enable the development of new applications that rely on a trusted connection between human, corporate, and device identities. Registered in Hong Kong, Blockpass IDN is a joint venture of Infinity Blockchain Labs and Chain of Things. Blockpass IDN licenses its technology from the non-profit Blockpass Foundation, registered in the Isle of Man.

    For more information and updates, please visit and sign up to the following:
    Promotional video: https://youtu.be/SvO2cw3e-SI
    Website: http://www.blockpass.org
    Medium: https://medium.com/@blockpass
    Twitter: https://twitter.com/BlockpassOrg
    Facebook: https://www.facebook.com/blockpassorg/
    Telegram: https://t.me/blockpass

    Contact: Caitlin Betts, +852 9733 4935, press@blockpass.org

     
    Copyright 2018 ACN Newswire. All rights reserved. www.acnnewswire.com

    0 0

    KINGSPORT, Tenn., Oct 26, 2018 - (ACN Newswire) - Eastman Chemical Company (NYSE:EMN) today announced reported earnings of $2.89 per diluted share for third quarter 2018 versus $2.22 per diluted share for third quarter 2017. Adjusted earnings were $2.34 per diluted share for third quarter 2018 versus $2.19 per diluted share for third quarter 2017. For detail of the adjustments and reconciliation to reported company and segment earnings for all periods presented, see Tables 3A and 4A.

    "Our third-quarter results reflect the contribution of our innovation-driven growth model, continued cost management, and disciplined capital allocation," said Mark Costa, Board Chair and CEO. "We delivered six percent top-line growth in our specialties, Advanced Materials and Additives & Functional Products, and sequentially stable earnings in Fibers. The operating results and a lower effective tax rate resulted in solid year-over-year EPS growth. This performance, especially when considering global economic uncertainty, gives us confidence in the resiliency of our portfolio and the sustainability of our strong cash flow going forward."

    Segment Results 3Q 2018 versus 3Q 2017

    Additives & Functional Products - Sales revenue increased primarily due to higher selling prices across most product lines. Reported EBIT included coal gasification incident insurance in excess of costs in third quarter 2018. Reported and adjusted EBIT decreased slightly primarily due to higher raw material and energy costs and increased growth investments, partially offset by higher selling prices and volume growth.

    Advanced Materials - Sales revenue increased primarily due to higher sales volume and continued improvement in product mix across the segment, including premium products such as Tritan(TM) copolyester, Saflex(R) head-up displays ("HUD"), and performance films. Reported EBIT included coal gasification incident insurance in excess of costs in third quarter 2018. Reported and adjusted EBIT increased primarily due to higher sales volume and improved product mix of premium products, partially offset by higher raw material and energy costs and increased growth investments.

    Chemical Intermediates - Sales revenue increased due to higher selling prices across most product lines, particularly for acetyl derivatives attributed to favorable market conditions and for olefin derivatives due to higher raw material and energy prices. Lower sales volume was primarily due to lower merchant ethylene sales. Reported EBIT included coal gasification incident insurance in excess of costs in third quarter 2018. Excluding this unusual item, adjusted EBIT decreased slightly due to lower sales volume being offset by higher selling prices more than offsetting higher raw material and energy costs.

    Fibers - Sales revenue decreased primarily due to lower acetate tow sales volume attributed to customer buying patterns and lower acetate tow selling prices attributed to lower industry capacity utilization. The lower sales revenue was partially offset by sales of nonwovens innovation platform products previously reported in "Other" and strong volume growth in our textiles innovation platform. Reported EBIT included coal gasification incident insurance in excess of costs in third quarter 2018. Excluding this unusual item, adjusted EBIT decreased primarily due to lower acetate tow sales volume and selling prices, partially offset by higher textiles innovation platform products sales volume and earnings.

    Cash Flow

    Eastman generated $395 million in cash from operating activities during third quarter 2018, primarily due to strong net earnings partially offset by increased working capital. Share repurchases totaled $125 million in third quarter 2018. See Table 5A.

    The company continues to expect to generate approximately $1.1 billion of free cash flow (cash from operating activities less net capital expenditures) in 2018. See Table 5B. Priorities for uses of available cash include payment of the quarterly dividend, repayment of debt, funding targeted growth initiatives and repurchasing shares.

    Outlook

    Commenting on the outlook for full-year 2018, Costa said: "During the first nine months of the year, we delivered a 13 percent year-over-year increase in adjusted earnings per share. This performance continues to be driven by strong volume growth in the specialty segments leveraging our innovation-driven growth model, as well as continued disciplined cost management, use of our robust free cash flow and a lower effective tax rate. Despite facing challenges in the global economy, we remain confident in our expectations for adjusted 2018 EPS growth to be between 10-14 percent."

    The full-year 2018 projected earnings exclude any non-core, unusual, or non-recurring items in the remaining three months of 2018 and assume that the adjusted effective tax rate detailed in Tables 4A and 4B for first nine months 2018 will be the actual rate for full-year 2018. Our 2018 financial results forecasts do not include non-core items (such as mark-to-market pension and other postretirement benefit gain or loss) or any unusual or non-recurring items, and we accordingly are unable to reconcile projected full-year 2018 earnings excluding non-core and any unusual or non-recurring items to reported GAAP earnings without unreasonable efforts.

    Tax Items and Revenue Recognition Accounting Change

    In the fourth quarter 2017, the Company recognized a provisional net increase to earnings of $339 million as a result of tax law changes, primarily the Tax Cuts and Jobs Act of 2017, and tax impact of outside-U.S. entity reorganizations, subject to adjustment during 2018. In third quarter 2018, the Company recognized a net increase of $14 million to the prior provisional net tax benefit primarily due to income taxes related to foreign income inclusion and associated foreign tax credits.

    Beginning in first quarter 2018, the Company adopted Accounting Standards Codification 606 under which the Company recognizes revenue when control of goods has been transferred to the customer, generally at the time shipment occurs. Under the previous revenue recognition accounting standard, the Company recognized revenue upon delivery of goods. Third-quarter 2018 EBIT under the new method of revenue recognition was $4 million higher than it would have been under the former method of revenue recognition.

    Forward-Looking Statements

    This news release includes forward-looking statements concerning current expectations and assumptions for future global economic conditions; competitive position and acceptance of specialty products in key markets; mix of products sold; raw material and energy prices and costs, and other costs; and revenue, earnings, and cash flow for full-year 2018. Such expectations and assumptions are based upon certain preliminary information, internal estimates, and management assumptions, expectations, and plans, and are subject to a number of risks and uncertainties inherent in projecting future conditions, events, and results. Actual results could differ materially from expectations and assumptions expressed in the forward-looking statements if one or more of the underlying assumptions or expectations prove to be inaccurate or are unrealized. Important factors that could cause actual results to differ materially from such expectations are and will be detailed in the company's filings with the Securities and Exchange Commission, including the Forms 10-Q filed for second quarter 2018 available, and the Form 10-Q to be filed for third quarter 2018 and to be available, on the Eastman web site at www.eastman.com in the Investors, SEC filings section.

    Conference Call and Webcast Information

    Eastman will host a conference call with industry analysts on October 26, 2018 at 8:00 a.m. ET. To listen to the live webcast of the conference call and view the accompanying slides, go to www.investors.eastman.com, Events & Presentations. To listen via telephone, the dial-in number is 719-457-1036, passcode number 3914147. A web replay, a replay in downloadable MP3 format, and the accompanying slides will be available at www.investors.eastman.com, Events & Presentations. A telephone replay will be available continuously from 11:00 a.m. ET, October 26, 2018 to 11:00 a.m. ET, November 5, 2018 at 888-203-1112 or 719-457-0820, passcode 3914147.

    Eastman is a global advanced materials and specialty additives company that produces a broad range of products found in items people use every day. With a portfolio of specialty businesses, Eastman works with customers to deliver innovative products and solutions while maintaining a commitment to safety and sustainability. Its market-driven approaches take advantage of world-class technology platforms and leading positions in attractive end-markets such as transportation, building and construction, and consumables. Eastman focuses on creating consistent, superior value for all stakeholders. As a globally diverse company, Eastman serves customers in more than 100 countries and had 2017 revenues of approximately $9.5 billion. The company is headquartered in Kingsport, Tennessee, USA and employs approximately 14,000 people around the world. For more information, visit www.eastman.com.

    Contacts:
    Media: Tracy Kilgore Addington
    423-224-0498 / tracy@eastman.com

    Investors: Greg Riddle
    212-835-1620 / griddle@eastman.com

    ex99_01 2018.09.30 CC Tables 2018.10.25 PM: http://hugin.info/150386/R/2222310/870265.PDF

    ###

    This announcement is distributed by West Corporation on behalf of West Corporation clients.
    The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
    Source: Eastman Chemical Company via Globenewswire

     
    Copyright 2018 ACN Newswire. All rights reserved. www.acnnewswire.com

    0 0

    At the 11th Clinical Trials in Alzheimer's Disease Conference

    TOKYO, Oct 26, 2018 - (JCN Newswire) - Eisai Co., Ltd. announced that Eisai presented new data from Study 202, a Phase II evaluation of lemborexant, an investigational sleep-wake regulation agent, for the treatment of Irregular Sleep-Wake Rhythm Disorder (ISWRD) in patients with mild to moderate Alzheimer's disease. The data were presented at the 11th Clinical Trials in Alzheimer's Disease (CTAD) Conference in Barcelona, Spain. Lemborexant is being developed for the treatment of multiple sleep-wake disorders, including insomnia disorder.

    ISWRD is a type of circadian rhythm sleep disorder where the pattern of sleep and wakefulness that repeats itself over a 24-hour period in healthy individuals is broken down, and sleeping and waking occur instead at various times during the day and night. This is often observed in patients with neurodegenerative diseases such as Alzheimer's disease. There is no known treatment approved for an irregular sleep-wake pattern in patients, meaning this is a condition with high unmet medical need.

    Study 202 was a global, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of lemborexant in 62 patients 64 to 89 years of age with ISWRD and mild to moderate Alzheimer's disease. The primary objective of this study was to provide proof of concept of lemborexant's effects on ISWRD by evaluating the change from baseline in circadian rhythm-related parameters, nighttime sleep-related parameters and daytime wake-related parameters using actigraphy over four weeks of treatment. An actigraph is a non-invasive device worn on the wrist that incorporates a multidirectional accelerometer to monitor degree and intensity of motion. Actigraphs are approved as medical devices that can measure sleep-wake patterns over a 24 hour period by fitting collected activity data into an algorithm.

    The study evaluated four doses of lemborexant (2.5mg, 5mg, 10mg and 15mg) versus placebo. Treatment with lemborexant resulted in an improved 24-hour circadian rhythm pattern with statistically significant reductions in nighttime activity compared to placebo after four weeks of treatment at three of the four doses tested (2.5mg, 5mg, and 15mg). Treatment with lemborexant also helped to consolidate nighttime sleep with positive trends, not statistically significant, for less fragmented and longer total sleep time during the night. Finally, the duration of unintentional daytime naps tended to be shorter with lemborexant treatment compared to placebo.

    The most common adverse events were constipation, somnolence, arthralgia, headache and nightmare. Most adverse events were mild to moderate and infrequent. No patients discontinued the study. There was no change with treatment on cognition as measured by the Mini-Mental State Examination (MMSE) or Alzheimer's Disease Assessment Scale for cognition (ADAS-Cog) that would indicate impairment.

    "ISWRD is a serious and debilitating condition and coupled with dementia puts patients at risk for falls when awake and wandering in the middle of night and poses considerable burden to the family members and caregivers of these patients," said Phyllis Zee, MD. PhD, Professor of Neurology at Northwestern University. "The results of Study 202 are encouraging for the potential further development of lemborexant for the treatment of ISWRD."

    By acting on the orexin neurotransmitter system, which is the primary regulator of the appropriate balance between sleep and wake at the appropriate circadian times, lemborexant appears to impact the underlying reason for a patient's inability to sleep well.

    "Our aspiration is to develop lemborexant as a first-in-class medicine for ISWRD to improve sleep and wake patterns for patients with dementia, and as a best-in-class medicine for insomnia disorder" said Lynn Kramer, MD, Chief Clinical Officer and Chief Medical Officer, Neurology Business Group, Eisai. "We are encouraged by the results of Study 202 in patients with ISWRD and as we conduct additional analyses, we will look forward to engaging experts in the field and health authorities regarding a potential path forward for full development, aiming to contribute to patients through lemborexant."

    Eisai is striving to create innovative medicines through a holistic and multi-dimensional approach to dementia drug discovery research based on a foundation of over 30 years of experience of drug discovery activities in the area of Alzheimer's disease / dementia. Through research and development on lemborexant, Eisai is striving to fulfill new unmet medical needs in ISWRD and dementia in addition to insomnia to further contribute to increasing the benefit for patients and their families.

    About lemborexant

    Lemborexant (development code: E2006), a dual orexin receptor antagonist, is an in-house discovered and developed small molecule compound by Eisai which inhibits orexin by binding competitively to two subtypes of orexin receptors (orexin receptor 1 and 2). In individuals with insomnia disorder, it is possible that the orexin system which regulates sleep and wakefulness is not functioning normally. During normal periods of sleep, orexin system activity is suppressed, suggesting it is possible to purposefully facilitate the initiation and maintenance of sleep by interfering with orexin neurotransmission with lemborexant.

    Eisai and Purdue Pharma are investigating lemborexant as a potential treatment option for sleep-wake disorders. In addition to investigation for the potential treatment of ISWRD in patients with Alzheimer's Disease, Eisai and Purdue are developing lemborexant for the treatment of insomnia disorder, and Phase III studies for the treatment of insomnia have now been completed.
    Information about ongoing clinical studies is available at clinicaltrials.gov.

    About ISWRD (Irregular Sleep-Wake Rhythm Disorder)

    ISWRD is a type of circadian rhythm sleep disorder where the pattern of sleep and wakefulness that repeats itself over a 24-hour period in healthy individuals is broken down, and sleeping and waking occur instead at various times during the day and night. This is often observed in patients with dementia. Although referred to in this press release as ISWRD, the condition is also known as a Circadian Rhythm Sleep Disorder - Irregular Sleep Wake Type.

    About Study 202

    Study 202 is a multicenter, randomized, double-blind, placebo-controlled, parallel-group Phase II clinical study (with an open-label extension) of the efficacy and safety of lemborexant in subjects with ISWRD and mild to moderate Alzheimer's disease dementia conducted in the United States, Japan and the United Kingdom. Patients with ISWRD associated with Alzheimer's disease were administered 2.5 mg, 5 mg, 10 mg or 15 mg of lemborexant or placebo for 4 weeks to determine whether lemborexant would lead to improvement in circadian rhythm, nighttime sleep or daytime wake variables, as measured by actigram. Subjects diagnosed with Alzheimer's disease who also met the Diagnostic and Statistical Manual of Mental Disorders - 5th edition (DSM-5) and the 10th revision of the International Classification of Diseases (ICD-10) criteria for ISWRD were screened with actigraphy to ensure current patterns of ISWRD, and then were randomized to one of four doses of lemborexant or placebo. Actigraphy was recorded continuously during the screening period, for the 1-month treatment period, and a 2-week follow-up period.

    About Actigraphy

    An actigraph is a non-invasive device worn on the wrist that incorporates a multidirectional accelerometer to monitor degree and intensity of motion. This device consists of a compact, wrist-worn, battery-operated activity monitor which looks like a wrist watch. Actigraphs are approved as medical devices that can measure sleep-wake patterns over a 24 hour period by fitting collected activity data into an algorithm. As innovative endpoints using actigraphy, Study 202 evaluated the changes in circadian rhythm-related parameters, nighttime sleep-related parameters and daytime wake-related parameters between baseline and the final week of treatment.

    About Eisai

    Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our human health care philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Oncology and Neurology.

    As a global pharmaceutical company, our mission extends to patients around the world through our investment and participation in partnership-based initiatives to improve access to medicines in developing and emerging countries.

    For more information about Eisai Co., Ltd., please visit www.eisai.com.

    Contact:
    Media Inquiries: Public Relations Department Eisai Co., Ltd. +81-(0)3-3817-5120

    Copyright 2018 JCN Newswire. All rights reserved. www.jcnnewswire.com

    0 0

    Product businesses in the "Industry/Distribution/Water" domain will be strengthened with an eye on the preparation of "2021 Mid-term Management Plan"

    TOKYO, Oct 26, 2018 - (JCN Newswire) - Hitachi, Ltd. (TSE:6501) has today decided to spin off the Industrial Products Business Unit that operates the business of large-sized industrial equipment as Hitachi Industrial Products, Ltd., a company which will be newly established, to strengthen the product business in the "Industry/Distribution/Water" domain, one of Hitachi's four focus business domains; "Power/Energy", "Industry/Distribution/Water", "Urban" and "Finance/Social/Healthcare." The spin-off will take place on April 1, 2019.

    Through the spin-off, Hitachi will build an organizational structure in which its industrial equipment business is integrated into two companies, namely, Hitachi Industrial Products, a new company that undertakes large-sized industrial equipment with a focus on build-to-order items and Hitachi Industrial Equipment Systems Co., Ltd. (Hitachi Industrial Equipment Systems), a company that handles industrial equipment consisting mainly of mass-produced items. It will seek to achieve a flexible business operation as independent operating companies and dramatically strengthen manufacturing. In doing so, it will provide highly competitive products on a global basis.

    To proceed with the reorganization, Hitachi's Industrial Products Business Unit will be taken over by a company that will be established in the near future through an absorption-type split.

    The disclosure items and details on the Company Split have been partially omitted since this is an absorption-type split in which a wholly owned subsidiary takes over a business from Hitachi.

    Purpose of Company Split

    Hitachi established the current Industrial Products Business Unit as an integrated organization for large-sized industrial equipment businesses in 2015, and through such efforts, has been working to strengthen its business base and enhance product competitiveness and profitability. Now, with an eye on the preparation of its "2021 Mid- term Management Plan," which begins in fiscal 2019, it has decided to conduct a reorganization to spin off the Industrial Products Business Unit as Hitachi Industrial Products, a company which will be newly established.
    As an independent operating company, the new company will expedite its decision- making processes, operate in a way flexible enough to compete with specialized companies, and establish an organizational structure in which products that can aim for the top positions on a global basis can be developed and supplied promptly. In addition, it will continue to strengthen its competitiveness globally by optimizing each operational process from manufacturing, sales to services, in addition to leveraging its competitive manufacturing capability utilizing digital technologies.

    Through the reorganization, Hitachi Industrial Products that operates with a focus on build-to-order items and Hitachi Industrial Equipment Systems which mainly handles mass-produced items will lead Hitachi's product business under common business strategies, globally, while at the same time playing an important role in the Social Innovation Business of Hitachi, whose strength is the capability of offering Products, Operational Technology (OT) and Information Technology (IT) comprehensively.

    In addition, Hitachi will also bolster the business administration function of developing strategies on a cross-functional basis across business units and group companies in the "Industry/Distribution/Water" domain, so that business strategies can be executed in a manner that unifies the front-line promoting Lumada-based digital solution businesses and its competitive product business. It will seek to establish an optimal business structure in the industrial area by promoting the digital solution business and connected products business.

    About Hitachi, Ltd.

    Hitachi, Ltd. (TSE: 6501), headquartered in Tokyo, Japan, delivers innovations that answer society's challenges, combining its operational technology, information technology, and products/systems. The company's consolidated revenues for fiscal 2017 (ended March 31, 2018) totaled 9,368.6 billion yen ($88.4 billion). The Hitachi Group is an innovation partner for the IoT era, and it has approximately 307,000 employees worldwide. Through collaborative creation with customers, Hitachi is deploying Social Innovation Business using digital technologies in a broad range of sectors, including Power/Energy, Industry/Distribution/Water, Urban Development, and Finance/Social Infrastructure/Healthcare. For more information on Hitachi, please visit the company's website at http://www.hitachi.com.

    Contact:
    Hitachi Ltd Corporate Communications Tel: +81-3-3258-1111

    Copyright 2018 JCN Newswire. All rights reserved. www.jcnnewswire.com

    0 0

    TOKYO, Oct 26, 2018 - (JCN Newswire) - NEC Corporation (TSE: 6701) announced that it is supporting the Stanford DAWN project, an initiative to simplify the building of AI-powered applications, by providing a cluster of new "SX-Aurora TSUBASA" vector computers for research in the area of artificial intelligence (AI).

    In recent years, a broad range of applications using AI have been proposed. However, since AI processing requires enormous computational power, there are many cases where it is difficult to adopt.

    In order to help address this issue, NEC has provided four SX-Aurora TSUBASA A300-4 models to the Stanford DAWN project in order to contribute to AI research. The SX-Aurora TSUBASA is NEC's latest model of vector supercomputer, featuring scalability from a desktop computer to a large super computer for accelerating AI and data analytic applications.

    Yuichi Nakamura, vice president, NEC Central Research Laboratories, said: "We are very pleased to support the Stanford DAWN project. We hope to help demonstrate the value of vector computing to the advancement of AI domains."

    NEC aims to accelerate the progress of AI research and development and to contribute greater value to society with the achievements of this collaboration.

    About NEC Corporation

    NEC Corporation is a leader in the integration of IT and network technologies that benefit businesses and people around the world. The NEC Group globally provides "Solutions for Society" that promote the safety, security efficiency and fairness of society. Under the company's corporate message of "Orchestrating a brighter world," NEC aims to help solve a wide range of challenging issues and to create new social value for the changing world of tomorrow. For more information, visit NEC at https://www.nec.com.

    Contact:
    NEC Seiichiro Toda s-toda@cj.jp.nec.com +81-3-3798-6511

    Copyright 2018 JCN Newswire. All rights reserved. www.jcnnewswire.com

    0 0

    TOKYO and STOCKHOLM, Oct 26, 2018 - (ACN Newswire) - Fujitsu Limited and Ericsson (NASDAQ: ERIC) have entered an agreement to deliver end-to-end 5G network solutions and related services under a strategic partnership. The two companies are joining forces to develop this based on their combined portfolios - spanning radio access and core network - for the dynamic 5G market in Japan, connecting communications service providers to the global 5G ecosystem.

    The two companies aim to initially provide systems and solutions for the Japanese market, and seek to further expand their collaboration to other customers globally.

    In the 5G era, mobile communications service providers anticipate the ability to provide highly scalable, and intelligent services through open and globally standardised technology for core and radio access network for more efficient network operations.

    As a leading network technology provider, Fujitsu is making concerted efforts to support open standards activities driven by major telecommunications providers and aims to achieve broad interoperability for its radio access products in global markets.

    As a world leader in 5G, Ericsson has worked closely with mobile operators around the world in the development of 5G, through standardization, trials, and prototyping.

    Ericsson and Fujitsu's strength in research and development will ensure the best path for bringing global 5G solutions to Japan, as well as exploring a wider global market.

    Tango Matsumoto, Executive Vice President, Head of Network Business Group at Fujitsu, says: "Through this partnership with Ericsson, we will provide flexible 5G network systems that are open and standard compliant, and will leverage our expertise in wireless technologies and network integration to a wide range of customers in and outside of Japan. From mobile broadband, expected to be the first widespread use case of 5G, to the Internet of Things (IoT) and beyond, this partnership holds out the promise of exciting new business opportunities."

    Fredrik Jejdling, Executive Vice President and Head of Business Area Networks at Ericsson says: "Our global expertise in 5G combined with our understanding of the local market puts us in an excellent position to support the introduction of 5G in Japan. By working closely with operators and partners, we are creating solutions that will bring successful use cases and applications to the market. With Fujitsu we get an excellent partner to accelerate this development."

    For media kits, backgrounders and high-resolution photos, please visit www.ericsson.com/press.

    About Ericsson
    Ericsson enables communications service providers to capture the full value of connectivity. The company's portfolio spans Networks, Digital Services, Managed Services, and Emerging Business and is designed to help our customers go digital, increase efficiency and find new revenue streams. Ericsson's investments in innovation have delivered the benefits of telephony and mobile broadband to billions of people around the world. The Ericsson stock is listed on Nasdaq Stockholm and on Nasdaq New York. www.ericsson.com

    More information: ericsson.com/news
    media.relations@ericsson.com
    (+46 10 719 69 92)
    investor.relations@ericsson.com
    (+46 10 719 00 00)

    About Fujitsu
    Fujitsu is the leading Japanese information and communication technology (ICT) company, offering a full range of technology products, solutions, and services. Approximately 140,000 Fujitsu people support customers in more than 100 countries. We use our experience and the power of ICT to shape the future of society with our customers. Fujitsu Limited (TSE: 6702) reported consolidated revenues of 4.1 trillion yen (US $39 billion) for the fiscal year ended March 31, 2018. For more information, please see www.fujitsu.com.

    Fujitsu
    Public & Investor Relations
    T: +81-3-3215-5259
    U: www.fujitsu.com/global/news/contacts/
    This release is available at www.fujitsu.com/global/about/resources/news/press-releases/



     
    Copyright 2018 ACN Newswire. All rights reserved. www.acnnewswire.com

    0 0

    Coming to Chicago on December 11, by Blockchain China Connect and Artisan Business Group

    CHICAGO, IL, Oct 27, 2018 - (ACN Newswire) - Marketing Blockchain Project & Raising International Investments Workshop is coming to Chicago on December 11, 2018. The Chicago Workshop is organized by Blockchain China Connect and Artisan Business Group. This interactive marketing workshop for the blockchain and cryptocurrency industry will discuss how to promote your project and facilitate investment capital from across the world, with specific focus on Chinese and Asian investors.

    Blockchain entrepreneurs and cryptocurrency investors are expected to attend and discuss the latest market and investment trends, marketing techniques, and regulatory updates in the blockchain and cryptocurrency industry. The one-day workshop provides industry professionals and practitioners a great opportunity of peer-to-peer networking and exploring investment, business and collaborations.

    Topics for the sessions will include; Current Blockchain Investment Environment and Trends in Asia and China, International Regulatory and Compliance Issues, Utilizing Local Blockchain Media to Gain Popularity, Understanding Asian Private and Institutional Investors, Launching ICOs and Getting Listed and Traded, and International Negotiations and Partnership. Expert speakers and panelists include Brian Su of Artisan Business Group, Tyler McKay of Blockchain China Connect, Andy Wang of FutureChain and Rob Tiv of Sonic Messenger. Industry media partners from China and the US will cover the event.

    The Chicago blockchain marketing workshop will focus on how ICOs, STOs and Blockchain focused projects can raise investment through road shows, private meetings with investors and international institutional partnerships. There will be lively discussions about the future of Bitcoin, Ethereum and Litecoin including conversation about the most popular coins in China such as NEO, VeChain, Wanchain, EOS and more.

    Other topics include updates on Chinese cryptocurrency regulations, and US securities & regulations impacting ICO such as Reg D., Reg S. Reg A+, KYC and AML. ICO pitch, exhibitors and sponsors are welcome to contact us for promotional packages. The official venue for the event is Hilton Garden Inn -Chicago O'Hare Airport.

    Online registration at the event website: www.BlockchainChinaConnect.com.
    Sponsorship, BTC payment and offline registration, please contact us:
    Mr. Tyler McKay,1-217-899-6661, tyler@BlockchainChinaConnect.com
    Welcome to bookmark our daily blog at http://www.CryptoChinaBlog.com!

     
    Copyright 2018 ACN Newswire. All rights reserved. www.acnnewswire.com

older | 1 | .... | 303 | 304 | (Page 305) | 306 | 307 | .... | 320 | newer